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Innate immune recognition of extracellular host-derived self-DNA and self-RNA is
prevented by endosomal seclusion of the Toll-like receptors (TLRs) in the
dendritic cells (DCs). However, in psoriasis plasmacytoid dendritic cells have
been found to be able to sense self-DNA molecules in complex with the
endogenous cationic antimicrobial peptide LL37, which are internalized into the
endosomal compartments and thus can access TLR9. We investigated whether
this endogenous peptide can also interact with extracellular self-RNA and lead to
DC activation. We found that LL37 binds self-RNA as well as self-DNA going into
an electrostatic interaction; forms micro-aggregates of nano-scale particles
protected from enzymatic degradation and transport it into the endosomal
compartments of both plasmacytoid and myeloid dendritic cells. In the
plasmacytoid DCs, the self-RNA-LL37 complexes activate TLR7 and like the selfDNA-LL37 complexes, trigger the production of IFN-α in the absence of induction
of maturation or production of IL-6 and TNF-α. In contrast to the self-DNA-LL37
complexes, the self-RNA-LL37 complexes are also internalized into the
endosomal compartments of myeloid dendritic cells and trigger activation through
TLR8, leading to the production of TNF-α and IL-6, and the maturation of the
myeloid DCs.
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Furthermore, we found that these self nucleic acid-LL37 complexes can be found
in vivo in the skin lesions of the cutaneous autoimmune disease psoriasis, where
they are associated with mature mDCs in situ. On the other hand, in the systemic
autoimmune disease systemic lupus erythematosus, self-DNA-LL37 complexes
were found to be a constituent of the circulating immune complexes isolated from
patient sera. This interaction between the endogenous peptide with the self
nucleic acid molecules present in the immune complexes was found to be
electrostatic and it confers resistance to enzymatic degradation of the nucleic
acid molecules in the immune complexes. Moreover, autoantibodies to these
endogenous peptides were found to trigger neutrophil activation and release of
neutrophil extracellular traps composed of DNA, which are potential sources of
the self nucleic acid-LL37 complexes present in SLE immune complexes.
Our results demonstrate that the cationic antimicrobial peptide LL37 drives the
innate immune recognition of self nucleic acid molecules through toll-like
receptors in human dendritic cells, thus elucidating a pathway for innate sensing
of host cell death. This pathway of autoreactivity was found to be pathologically
relevant in human autoimmune diseases psoriasis and SLE, and thus this study
provides new insights into the mechanisms autoimmune diseases.
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1. General Introduction
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1.1. Immune recognition of self vs. non-self: paradigmatic shifts
The immune system in higher organisms is thought to operate based on some
algorithm for discriminating self from nonself. Besides being resident in the body,
the ‘self’ can also be depicted as any bodily molecular entity that is defined early
in life and the ‘nonself’ as any entity that the body encounters later in life. Scads
of cerebration has gone into elucidating this basic operating principle of immune
system that decides whether any molecular entity will face the immune restrains
or not. The experiments, which for the first time proved that the immune system
do recognize self and do not mount responses against them, were reported by
Paul Ehrlich (Ehrlich P and Morgenroth J, 1957). Since then the most widely
accepted model had been the aforesaid discrimination of self from nonself.
The ‘self-nonself’ (SNS) model proposed by Burnet has been the first wellstructured suggestion toward a uniform logistics for the immune operations that
proposed that the lymphocytes are the principal architects for building up an
immune response — each lymphocyte expresses multiple copies of a single
surface receptor specific for a foreign entity; signaling through this surface
receptor initiates the immune response, and lymphocytes having receptors that
recognize self proteins are deleted early in life (Burnet FM, 1959). The
observation that the activated B cells undergo somatic hypermutation later in life
and in the process generate potentially hyperreactive clones to result in
autoimmunity, required incorporation of some other immune cells for helping the
lymphocytes to avoid mounting response out of newly arisen self reactive
immune receptors. Thus the introduction of the ‘helper T cells’ by Bretscher and
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Cohn brought the first modification into the SNS model in 1970 (Bretscher P and
Cohn M, 1970).
Introducing the notion of ‘co-stimulation’ was the third and perhaps the most
important makeover that the SNS model experienced. Responding to the reports
that the T cells show stronger response against foreign cells from the same
species than against cells from other species, Lafferty and Cunningham added
another cell and another ‘signal’ to the prevailing model. They coined the term
‘co-stimulation’ for this newly envisaged signal and suggested that this is
species-specific (Lafferty KJ and Cunningham A, 1975). But the suggestion of
co-stimulation was not at all fully compatible with the original propositions of the
SNS model. Because these second group of cells (named by Lafferty and
Cunningham as the ‘stimulator cells’ and now called the ‘antigen presenting
cells’) do not have antigen-specific recognition receptors.
To incorporate the concept of co-stimulation into the SNS model in a more
justifiable way, Janeway suggested that the APCs might be envisaged to have
their own self-nonself discrimination modules that recognize some molecular
patterns on evolutionarily distant pathogens and thus serving to alert the
lymphocytes about the potential pathogenicity of the invading organisms
(Janeway CA Jr., 1989). He termed these pathogenic signatures, discerned by
the APCs, as the Pathogen Associated Molecular Patterns or PAMPs. He named
the corresponding recognition receptors as the Pattern Recognition Receptors or
PRRs and proposed

them to be encoded in the germ line and highly conserved

across the species. According to this model the APCs, which are normally
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quiescent (‘immature’), are activated via these PRRs on recognizing the PAMPs
present on the invading organisms and upregulate the expression of the
molecular determinants of ‘co-stimulation’ (the co-stimulatory molecules) on their
surface, and offer them to activate the T cells in addition to presenting the
processed antigens. Thus PRRs allow the APCs to discriminate between
‘infectious non-self’ and ‘non-infectious self’.
Till date discreet families of pattern recognition receptors have been described,
e.g. toll-like receptors (TLRs), RIG-I like receptors (RLRs), NOD-like receptors
(NLRs) and C-type lectin receptors (CLRs).
More recently the ‘danger’ hypothesis proposed by Matzinger rethinks the
logistics of immune recognition in order to address few questions left
unanswered by the infectious non-self model and it proposes that the immune
system is designed to react to tissue damage rather than to foreignness and is
alarmed by signals from the injured tissues rather than by nonself recognition
(Matzinger P, 2002; Kono H et al, 2008). The immune cells respond in the
context of tissue injury (associated with microbial invasion or other endogenous
causes) and this activation is triggered by some danger associated molecular
patterns (DAMPs) derived from the stressed/damaged host cells (Figure 1.1).
The potentially immunogenic DAMPs are normally hidden inside the host cells
but get access to the exterior in case of host cell death followed by breach of cell
membrane integrity.
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Figure 1.1

Figure 1.1. The non-self recognition (‘stranger’) and ‘danger’ models of immune
recognition. According to the ‘stranger’ model of immune recognition, dendritic cells and
other antigen presenting cells get activated through triggering of their pattern recognition
receptors (PRRs) by different pathogen associated molecular patterns (PAMPs). This leads
to expression of the co-stimulatory molecules and production of pro-inflammatory cytokines
leading to an effective immune response. On the other hand the ‘danger’ model proposes
that the immune cells only respond to a context of tissue injury (associated with microbial
invasion or other endogenous causes) and this activation is triggered by some danger
associated molecular patterns derived from the stressed/damaged host cells. (Kono H et al,
2008, reproduced with permission from Nature Reviews Immunology)
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1.2. Dendritic cells: the immune sentinels
Dendritic cells are the professional antigen presenting cells with the ability to
present antigen to naïve T cells in the context of self-MHC molecules and induce
primary immune response. DCs circumvent the challenges of induction of T cell
immunity such as lower frequency of antigen-specific T cells and antigen-loaded
major histocompatibility complex (MHC) molecules exposed on the pathogeninfected cells, and lack of co-stimulatory molecule expression. DCs are the
migrating sentinels that sample antigen from peripheral tissues and carry them to
secondary lymphoid organs to present them to specific T cells (Figure 1.2). In
addition to migrating DCs, DCs that are resident in the lymph nodes can take up
soluble antigens that reach the lymph nodes by diffusion through lymphatics
(Itano AA et al, 2003), Upregulation of co-stimulatory molecules and chemokine
receptors on the DCs in response to pathogen-derived molecules and
inflammatory cytokine milieu in the tissue environment is important for the DCs to
be able to perform their functions.
Two major subsets have been defined among the dendritic cells. The
conventional DCs of myeloid lineage origin are called myeloid DCs (mDCs). The
other subset is defined by their ability of rapid production of type I interferons in
response to viral infection and because of their microscopic morphological
similarity with antibody producing plasma cells they are named as the
plasmacytoid DCs (pDCs).
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Figure 1.2

Figure 1.2. Dendritic cells play the immune sentinels in the body. Dendritic cells, the
professional antigen presenting cells in the body, develop from the dendritic cell precursors
in the bone marrow and circulate in the blood and sample antigens from different tissue
spaces. Encounter of antigens concomitantly with PAMPs is followed by antigen take-up
and processing and dendritic cell maturation. Mature DCs with cell surface MHC molecules
loaded with processed antigen and expression of co-stimulatory molecules migrate to the
draining lymphnodes and present the antigen an co-stimulation to the adaptive immune
cells. (Hackstein H et al, 2004, reproduced with permission from Nature Reviews
Immunology)
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Myeloid DC subset consists of further subtypes with different localization and
distinct functions. The mDCs in mouse spleen have two major types that can
drive T cell responses differently. The CD8α+ DC subset induces helper type 1 T
cell response, while the other CD8α− subset induces helper type 2 responses
(Maldonado-Lopez R et al, 1999; Pulendran B et al, 1999). It has also been
shown that CD8α+ DCs preferentially activate antigen-specific CD8+ T cells, while
CD8α− DCs preferentially induce CD4+ T-cell responses (Dudziak D, 2007). On
the other hand the human mDCs have been subcategorized into three subtypes
based on localization: (1) peripheral tissue resident, (2) secondary lymphoid
organ resident mDCs, and (3) circulating blood mDCs.
Among the peripheral tissue resident mDCs, subsets that localize the human skin
are found to be members of at least three distinguishable subsets. The first one
being the Langerhans cells (LCs) that reside in the epidermis. The mDCs
populating the dermis are again either CD1a+ DCs or CD14+ DCs (Valladeau J et
al, 2005). Epidermal and dermal DCs can be distinguished further by their
expression of distinct sets of surface proteins. While the epidermal LCs express
the lectins Langerin and DCIR, the dermal CD14+ DCs express a large number of
surface C-type lectins, e.g. DC-SIGN, DEC-205, LOX-1, CLEC-6, Dectin-1, and
DCIR, and variable TLRs recognizing bacterial PAMPs, e.g. TLR2, 4, 5, 6, 8, and
10 (Klechevsky E et al 2009). Thus the dermal CD14+ DC seem to be better
equipped for bacterial recognition in the skin. Although LCs have been reported
to express TLR1, 2, 3, 6, and 10 (Klechevsky E et al 2009), but other groups
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have found a limited or no TLR expression on the LCs (Banchereau J et al,
2009).
Initial description of the plasmacytoid dendritic cells (pDCs) termed these cells as
plasmacytoid T cells or plasmacytoid monocytes because of their plasma-cell like
morphology under the microscope and expression of the T‑cell marker CD4 or
the myeloid-cell markers MHC class II, CD36 and CD68 (Facchetti F et al, 2000).
Later on, virologists and immunologists in the 1980s defined a natural type-Iinterferon-producing cell (IPC) owing to its capacity to produce large amounts of
type I interferons (IFNs) following culture with viruses and simultaneous
expression of class I MHC molecules and revealed them to be the same as the
previously described plasmacytoid cells. In 1997 human plasmacytoid dendritic
cells were for the first time isolated from peripheral blood and the purified cells
were defined as CD4+CD11c- dendritic cell precursors (Grouard G et al, 1997).
Later they were found to produce 200-1000 times more type I interferons
compared to other blood cells after microbial challenge (Siegal FP et al, 1999). In
2001, it was reported that pDCs produced type I IFNs in response to CpGcontaining DNA (as found in DNA viruses and bacteria) but not to the viral
dsRNA-mimic polyinosinic–polycytidylic acid (poly I:C). In contrast, myeloid DCs
(mDCs) were shown to produce type I interferons and interleukin-12 (IL-12) in
response to poly I:C and they did not respond to CpG-containing DNA or CpG
ODNs (Kadowaki N et al, 2001). All of the CpG DNA molecules are not able to
activate pDCs to produce type I interferons equally. CpG ODNs are classified
into two main types, e.g. D-type (or A-type) CpG ODNs, which induce IFNγ
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IFNγ production by natural killer (NK) cells, and K-type (or B-type) CpG ODNs,
which induce proliferation and IL-6 and antibody production in B lymphocytes
(Verthelyi D et al, 2001; Vollmer J et al, 2004). Now it is established that the
A‑type CpG ODNs more efficiently induce IFNα production by pDCs that in turn
can activate NK cells (Hornung V et al, 2001; Gerosa F et al, 2005; Hanabuchi S
et al, 2006), whereas the B type CpG ODNs are much less efficient (Kadowaki N
et al, 2001; Vollmer J et al, 2004; Ito T et al, 2006). B type CpG ODNs rather
induce pDCs to produce IL‑6 and tumor necrosis factor (TNF) and they also can
induce proliferation and antibody production in B lymphocytes (Kadowaki N et al,
2001; Vollmer J et al). These studies suggested that pDCs have different
signaling pathways to respond to different types of CpG ODN.
Human pDCs circulating in the peripheral blood enter secondary lymphoid tissue
through the high endothelial venules (HEV) (Siegal FP et al, 1999). They are
defined as lineage-negative HLA-DR-positive cells expressing very high levels of
the IL-3 receptor α chain (or CD123). Some specific markers have also been
characterized that are expressed by the pDCs, such as BDCA-2, BDCA-4 and
ILT-7 (Cao W et al, 2006). PDCs express a different set of pattern recognition
receptors from the myeloid DCs (Kadowaki N et al, 2001). PDCs can recognize
viral nucleic acids through TLR7 (recognizes single stranded RNA) and TLR9
(recognizes DNA) and gets activated to rapidly produce large amounts of type I
IFN (Kadowaki N et al, 2001).
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Dendritic cells can and do contribute in the induction of humoral immunity as well
by their capacity to directly activate B cells (Jego G et al, 2005; Qi H et al, 2006).
MDCs have been shown to be able to carry captured antigens in subcellular
compartments that prevent degradation of the antigens and then present the
native antigens to B cells (Bergtold A et al, 2005; Batista FD et al, 2009).
Dendritic cells are also able to induce antigen-specific tolerance in both the
central lymphoid organs and in the periphery. The role of thymic DCs in
generating tolerance by deleting self-reactive T cells is well documented
(Fairchild PJ and Austyn JM, 1990; Volkmann A et al, 1997; Brocker T et al,
1997). Several studies have reported a role for DCs in the induction of peripheral
tolerance (Steinman RM et al, 2003; Dhodapkar MV et al, 2001). When immature
DCs present very low dose of a soluble antigen in the absence of the specific
maturation stimuli, it leads to deletion of the corresponding T cells and
unresponsiveness to antigenic re-challenge even with strong adjuvants (Hawiger
D et al, 2001). The similar tolerogenic property has also been reported in
immature DCs in the context of cell-associated antigen (Hugues S et al, 2002)
and dying cells (Liu K et al, 2002). In vitro experiments demonstrated that human
mDCs with an immature phenotype induce differentiation of anergic regulatory T
cells (Jonuleit H et al, 2000; Roncarolo MG et al, 2001). However, other studies
in mouse have shown that semi-mature rather than completely immature DCs
can tolerize naïve CD4+ T cells (Kleindienst P et al, 2005). Although yet to be
established in humans, reports have already indicated the presence of such
tolerogenic DCs in mice in vivo (Wakkach A et al, 2003). In mice, tolerogenic
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DCs could be induced by treatment of bone marrow cells with IL-10. Mouse
tolerogenic DCs derived in vitro display plasmacytoid morphology and secrete
high levels of IL-10 after stimulation (Wakkach A et al, 2003). The
immunomodulatory cytokine IL-10 seems to be a critical determinant in DCinduced hypo-responsiveness in T cells. Again a feedback source of IL-10 from
the regulatory T cells in turn may differentiate tolerogenic DCs.
Thus by simultaneously being the inducer of primary immune response to myriad
of pathogenic invasion in the body and regulator of immune response in
appropriate physio-pathological settings, dendritic cells have emerged to be the
major decision making cells harboring the key nodes in the immune circuitry. The
decisions involve both identifying the molecular entities they have to respond to
and the type of immune response to be initiated.

1.3. Toll-like receptors: discriminating self from non-self
Toll-like receptors (TLRs) are a family of germline-encoded cell surface pattern
recognition molecules containing an ectodomain with leucine-rich repeats, a
transmembrane domain and a characteristic cytoplasmic domain called the TIR
(Toll/IL‑1 receptor) domain. This family was first described in Drosophila as the
toll receptors, which get triggered in response to bacterial and fungal infections
followed by induction of downstream signaling, leading to expression of
inflammatory genes like those of the nuclear factor-κB (NF-κB) family of
transcription factors and antimicrobial peptides. The first mammalian TLR
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identified was TLR4 (Medzhitov R et al, 1997). Since then a number of other
mammalian toll-like receptor family members (11 in human and 12 in mice) have
been identified which recognize different molecular patterns on the pathogens.
Major group of the TLRs are expressed on the cell surface. The leucine-rich
repeats in the ectodomains of these molecules bind to unique molecular entities
on pathogens (PAMPs). For example, the bacterial cell-wall component
lipopolysaccharide is a ligand of TLR4 (Medzhitov R et al, 1997; Poltorak A et al,
1998), the bacterial cell wall lipoproteins and peptidoglycans are recognized by
TLR2 complexed with TLR1 or TLR6 (Aliprantis AO et al, 1999) and the bacterial
flagella protein flagellin is a ligand of TLR5 (Hayashi F et al, 2001). Thus the
TLRs, expressed on the host cell surface, detects and initiate responses to
invading microorganisms (Akira S et al, 2004).
Another group of TLRs are located inside the cell within the endosomallysosomal compartments, instead of being expressed on the cell surface (Akira S
et al, 2004). This group comprises of TLR3 (Alexopoulou L et al, 2001), TLR7
(Hemmi H et al, 2001; Lund JM et al, 2004), TLR8 (Heil F et al, 2004) and TLR9
(Hemmi H et al, 2000). The endosomal TLRs are specialized for detecting
microbial nucleic acids after microbes get phagocytosed and reach the
endosomal compartments (Figure 1.3).
Cognate ligands bind the TLRs and initiates downstream signaling through
recruitment of TIR domain containing intracellular adaptor molecules. This leads
to the formation of multi-component signal transduction complexes in the cytosol.

14

Figure 1.3

Figure 1.3. The family of toll-like receptors (TLRs) in humans. A molecular tree placing
the different human TLR family members based on sequence homology and ligand
specificity. (Gilliet M et al, 2008, reproduced with permission from Nature Reviews
Immunology)
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There are four major adaptor proteins — Myd88 (or the myeloid differentiation
primary-response gene 88), TIRAP (or the TIR-domain containing adaptor
protein), TRIF (or the TIRAP inducing IFNβ) and TRAM (or the TRIF-related
adaptor molecule). The adaptor molecules interact with the TLRs through the TIR
domains, with different combinations of the adaptors taking part in this interaction
in case of specific TLRs (Akira S et al, 2004).

This TLR-adaptor molecule

interactions in turn recruit other proteins to the signaling complex, which initiates
multiple downstream signaling pathways, leading to activation of NFkB or
mitogen-activated protein kinases (MAPKs) or recruitment of the IFN regulatory
factors (IRFs). These different pathways in turn result in the transcription of
genes encoding different cytokines, chemokines, co-stimulatory molecules or
other proteins, thereby sculpting the ensuing immune response (Akira S et al,
2004).
MyD88 serves as the key adaptor molecule for almost all the TLRs and it recruits
IRAKs or the IL-1-receptor associated kinases to these TLRs (except TLR3) and
to the IL-1 receptor. Accordingly, MyD88‑deficient mice fail to respond to IL-1 or
microbial components recognized by TLR2, TLR4, TLR5, TLR7 or TLR9 (Adachi,
O. et al, 1998; Akira S et al, 2004). Among the TLRs that use MyD88, TLR7 and
TLR9 wholly depend on MyD88. TLR2 can use both MyD88 and TIRAP. On the
other hand TLR4 signals through recruitment of MyD88, TIRAP, TRIF and TRAM
(Akira S et al, 2004).
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1.4. Immune recognition of nucleic acids: pathogens vs. the host
After it was discovered that bacterial DNA could stimulate cells of the mammalian
immune system through TLR9 (Hemmi H et al, 2000), it was closely followed by
the discovery of a group of related TLRs residing in the intracellular endolysosomal compartments. These TLRs, TLR3, TLR7, TLR8 and TLR9, have
significant sequence homology among them (Wagner H, 2004), and recognize
the nucleic acids. TLR9 was reported to detect DNA molecules with
unmethylated CpG-containing motifs commonly found in the viral and bacterial
genomes (Hemmi H et al, 2000; Bauer S et al, 2001). Synthetic oligonucleotides
rich in CpG dinucleotides have been shown to interact directly with the
ectodomain of TLR9 inducing conformational changes in the receptor, leading to
downstream signaling (Latz E et al, 2007). TLR7 and TLR8 recognize guanosineor uridine-rich single stranded RNA (ssRNA) molecules from viruses, the
synthetic imidazoquinoline compounds

(imiquimod and resiquimod) and

guanosine analogues (Lund JM et al, 2004; Heil F et al, 2004). TLR3 recognizes
double stranded RNA molecules of viral origin and its synthetic mimic polyI:C
(Akira S et al, 2004).
Some other independent sensory systems other than the TLRs, that can also
detect nucleic acids, not in the endosomes but in the cytosol, have recently been
discovered. Three genes identified both in humans and mice encode a group of
such proteins known as the RIG-I-like receptors (or RLRs) — RIG-I (or the
retinoic-acid-inducible gene I), MDA5 (or the Melanoma differentiation-associated
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antigen 5) and LGP2 (or the Laboratory of genetics and physiology 2)
(Yoneyama, M et al, 2007; Stetson DB et al, 2006). All of the RLRs are DExD/H
box RNA helicases. RIG-I and MDA5 also contain an N-terminal CARD or the
Caspase-recruitment domain. They bind to double stranded RNA molecules
poly(I:C), poly(A:U) (Yoneyama M et al, 2005) and, 5′-triphosphate RNA in case
of RIG-I (Hornung V et al, 2006; Pichlmair A et al, 2006). These molecules are
present in viral genomes and viral replication intermediates. All the RLRs recruit
a central adaptor molecule called IPS-1 (or the IFNB promoter stimulator 1)
resulting in a signaling complex with TRAF3 or the TNF-receptor-associated
factor 3, TBK1 or the TRAF-family-member-associated NF-κB activator-binding
kinase 1 and IKKε or the Inhibitor of NF‑κB kinase ε. This complex signals
through IRF3 and induce type I IFN expression (Kawai T et al, 2005; Seth RB et
al, 2005; Matsui, K. et al, 2006).
More nucleic acids sensing systems are being reported in recent years in
mammalian cells. A system of intracellular DNA sensors have been reported in
macrophages called the inflammasome, by which cytoplasmic DNA is able to
trigger inflammatory responses, through activation of caspases independent of
TLRs and IRFs (Muruve DA et al, 2008). Another newly discovered molecule
termed DAI (or the DNA-dependent activator of IRFs) is a cytosolic DNA sensor.
It binds double stranded DNA molecules, signals through TBK1 and IRF3 and
activate NF‑κB to induce type I IFN production (Takaoka A et al, 2007). In
addition to these nucleic acid recognition systems, RNAs with short stem-loops is
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able to activate PKR or the protein kinase R that depends on presence of
5′‑triphosphate (Nallagatla SR et al, 2007) and small RNA cleavage products are
derived from self RNA through the action of RNase-L activated by 2′,5′-linked
oligoadenylate. These small RNA fragments can amplify antiviral IFN responses
(Malathi K et al, 2007).
The fact that the designated receptors of the innate immune system can
differentiate between self nucleic acids from nucleic acids of microbial or other
foreign origin has been a long-standing enigma intriguing the immunologists over
the years. While the chemical structure of microbial and mammalian nucleic
acids is essentially similar, microbial DNA is immunogenic but mammalian DNA
is not. Later the heterogeneity of DNA sequence and structure between different
species has been revealed. The unmethylated cytidine in CpG motifs of DNA has
been shown to be the structural basis of its immune recognition. Thus bacterial
DNA rich in unmethylated CpG sequences activate toll-like receptor 9 in the
plasmacytoid dendritic cells. But this concept was questioned by a study that
showed that artificial relocation of TLR9 on the cell surface of the cells instead of
inside the endosomal compartments can enable it to recognize and respond to
self-DNA (Barton GM et al, 2006). Thus endosomal seclusion of the DNArecognizing TLR9 is another way of helping it to discriminate between DNA of
self and non-self origin. Viral and bacterial DNA get access to the endosomal
compartments in the dendritic cells after being phagocytosed while extracellular
self DNA is barred from entering those compartments (Barton GM et al, 2006).
Another recent study revealed that the phosphodiester backbone of the DNA
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molecule, which is similar in all species, is recognized by the TLR9 (Haas T et al,
2008). Moreover, presence of extracellular nucleases cause fast and efficient
degradation of self nucleic acids released into the extracellular spaces in the
body and prevent then from accessing the immune receptors. Thus, at least in
case of DNA, the discrimination between the nucleic acid molecules of self and
pathogenic origin is in effect through other important parameters, beyond the
structural differences in the molecules, like seclusion from the immune-receptor
containing compartments of the immune cells and efficient extracellular
degradation.
Mammalian cells have 5-10 times more RNA than DNA (Kariko K et al, 2005).
Also the antigen presenting cells are equipped with toll-like receptors that can
recognize viral RNA. TLR7 and TLR8 in plasmacytoid DCs and myeloid DCs are
able to recognize single stranded RNA species. On the other hand TLR3 in
myeloid DCs recognizes double stranded RNA. Thus the issue of discriminating
self-RNA from microbial RNA is similarly, if not more, important just like DNA. A
lot of studies have looked into whether the immunogenicity of RNA is also
regulated by means of structural modifications like DNA. RNA is known to
undergo different nucleoside modifications (Rozenski et al., 1999) that depend on
the types of RNA and where do the organism in question belong on the
evolutionary ladder. Human ribosomal RNAs (rRNAs) have been shown to
contain 10 fold more pseudouridine and 25 fold more 2’-O-methylated
nucleosides than ribosomal RNA molecules of bacterial origin. Interestingly,
rRNAs from human mitochondria, which is thought to be a remnant of eubacteria
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(Margulis and Chapman, 1998), show very few modifications (Bachellerie and
Cavaille, 1998). Also mammalian messenger RNAs (mRNAs) have been shown
to undergo different modifications, like 5-methylcytidine, N6-methyladenosine,
inosine, 2’-O-methylated nucleosides, N7-methylguanosine in contrast to
bacterial mRNA that shows no such nucleoside modifications (Bokar and
Rottman, 1998). Also a lot of these nucleoside modifications are unique to in
either microbial or mammalian RNA. Thus these may constitute an important
molecular pattern for the toll-like receptors to distinguish between RNA of self or
microbial origin. A recent study, that aimed at elucidating the role of nucleoside
modifications on the immunogenicity of RNA by using modified RNA species, has
been shown that modifying U, A, and C nucleosides can suppress the RNA
induced activation of human dendritic cells (Kariko K et al, 2005). In the same
study different TLRs were found to be responsive to RNA differently based on
modifications present and unmodified RNA molecules could activate all of them,
thus making a strong case for the RNA modifications to be the ultimate
determinants for origin discrimination and immunogenic potential. But other
studies have shown that modified nucleosides are also present in the many viral
RNAs like influenza, adeno, and herpes simplex and content of modified
nucleosides were found to be more in viral than in host cell mRNAs (Bokar and
Rottman, 1998). Thus nucleoside modification by itself cannot wholly explain the
self-nonself discrimination for ribonucleic acid molecules.
Keeping in mind all the experimental data, generated to explain how nature
conjures up an efficient system to recognize and respond to nucleic acid
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molecules of microbial origin while preventing autoreactivity, perhaps it will be
more prudent to think of a multipronged regulatory algorithm, based on
mechanisms like barring self nucleic acids from accessing the responsive
receptors, differential structural modifications and extracellular clearance of the
released self nucleic acids etc., which work together toward achieving a more
secure self-nonself discrimination.

1.5. Cell death sensing: ‘danger’-driven immune activation
Association of inflammatory response with tissue injury is well appreciated.
Mechanistically this association depends on different phenomena encountered in
injury. More often tissue injury is complicated by microbial invasion and that
leads to the usual innate and adaptive immune activation to the non-self entities
associated with microbes and in the process body tries to get rid of those
invading microbes. On the other hand, sterile tissue injury in the absence of
microbial presence is also found to incite immune activation and inflammation.
The inflammatory events associated with sterile tissue injury serves homeostatic
purposes. Vasodilatation that follows local tissue injury play a role in increasing
blood perfusion at the site of injury, thereby delivering blood-borne immune cells
and defense mediators to combat possible pathogen invasion. The increased
blood flow also helps to dilute and drain away the potential chemical mediators of
injury. Upregulated local expression of chemokines and vascular adhesion
molecules attract leukocytes to the site of injury that in addition to combating
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potential microbial invasion, play a role in sequestering the injurious agents to
prevent spread of injury, and to scavenge the cellular debris generated as a
result of cell death at the site of injury. Finally a local inflammation following
tissue injury serves to facilitate the repair mechanisms. The inflammatory
response in tissue injury results either from release of biochemical mediators
from the injured or dying cells or through activation of hemostatic pathways
following injury to blood vessels.
Although tissue injury and consequent cell death induces inflammatory
responses in the body, they are desired to be short lived. Release of intracellular
contents following host cell death poses the danger of presenting certain selfmolecular entities to the immune cell-associated pattern recognition receptors,
that might result in autoimmune activation. One of the important examples of
such self-molecules is the self nucleic acids released from dying cells. To prevent
exposure of such dead cell-derived potential immune mediators robust clearance
mechanisms are in place. The potential fall-out of the release of these mediators
following cell death is established through instances of autoimmune activation in
the context of clearance mechanism deficiency disorders. These include
phagocytic functions of recruited macrophages and neutrophils as well as the
extracellular nucleases and other enzymes.
In addition to injury-induced cell death, normal embryogenesis, development and
homeostasis are associated with continuous turnover of host cells though out the
life of the organisms. The physiological cell death mostly occurs through
apoptosis or the programmed cell death in contrast to the necrotic cell death in
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Figure 1.4

Figure 1.4. Necrotic cell death is immunogenic due to the exposure of the cell
associated danger signals. According to the ‘danger’ model the immune cells are
activated in the context of tissue injury (associated with microbial invasion or other
endogenous causes) and this activation is triggered by some danger associated molecular
patterns derived from the stressed/damaged host cells. The exposure of these DAMPs
occurs in the necrotic form of host cell death (the ‘pathological’ cell death) due to release of
intracellular contents following breach of cell membrane integrity. In contrast to this in
apoptosis (the ‘physiological’ cell death) intracellular contents of the dying cells are released
enclosed in membrane-bound vesicles which are efficiently cleared by phagocytic cells thus
preventing immune recognition and activation. (Kono H et al, 2008, reproduced with
permission from Nature Reviews Immunology)
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response to tissue injury. In apoptotic cell death the cell shrinks, chromatin
condenses, DNA gets fragmented, and then the cellular components are
encased in membrane-bound apoptotic vesicles. These apoptotic vesicles are
then rapidly and efficiently cleared by the recruited phagocytes. The process is
highly regulated and the plasma membrane of the dying cells remains intact,
thereby preventing release of intracellular components with potential immuneactivating properties, into the extracellular space (Figure 1.4). On the contrary,
necrotic cell death in response to infection or bodily injury is associated with
release of cytosolic and nuclear materials, including nucleic acids, into the
surrounding tissue spaces, resulting in immune cell recruitment and immune
activation (Figure 1.4). These different categories of cell death seem to be a
teleologically viable strategy, whereby a potent immune activation ensues in
response

to

pathological

cell

death,

preventing

immune

activation

to

physiological cell death. However, deficient or delayed clearance of apoptotic
cells makes the process continue to secondary necrosis characterized by loss of
plasma membrane integrity and release of intracellular contents. Secondary
necrosis thus poses the danger of triggering pro-inflammatory immune activation.
Recent studies have identified a number of molecules of self-origin that get
released in tissue injury and cell death and alert the immune system about the
impending or ongoing ‘danger’. To appreciate similarity of these molecules with
the PAMPs, or the molecular patterns on pathogens that incite immune response
in case of a foreign invasion, at times these self-molecules are termed ‘DAMPs’
or the Danger Associate Molecular Patterns (Kono H et al, 2008). A bona fide
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DAMP molecule should fulfill certain criteria like being active in pure form (activity
not due to contaminating PAMPs) and active at patho-physiologically relevant
concentrations. A number of candidates for such molecules have been proposed
and identified over the past several years. Some of the established DAMPs are
heat shock proteins (Basu S et al, 2000), uric acid (Shi Y et al, 2003), the high
mobility group box 1 protein or HMGB1 (Lotze MT et al, 2005) and double
stranded genomic DNA (Lande R et al, 2007).

1.6. Psoriasis: cutaneous autoimmunity
Psoriasis is a chronic, inflammatory disease of the skin characterized by sharply
demarcated scaly erythematous plaques. It is one of the longest known illnesses
of humans. On the other hand it is one of the most elusive and misinterpreted
one. Psoriasis was frequently confused as a type of leprosy due to resemblance
in morphology. The Greeks used the term ‘lepra’ (λεπρα) for scaly skin conditions
and the term ‘psora’ to describe itchy skin conditions. In the late 18th century it
came to be called as Willan's lepra after the English dermatologists Robert Willan
and Thomas Bateman who perhaps for the first time differentiated it from other
skin diseases. Thus it has always been visually, and later semantically, confused
with leprosy and it was not until 1841 that the Viennese dermatologist Ferdinand
von Hebra gave the name psoriasis for this disease, derived from the Greek word
psora which means to itch (Freedberg, et al., 2003). During the 20th century
studies identified specific types of psoriasis of which there are five major types:
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plaque, guttate, inverse, pustular and erythrodermic. Plaque psoriasis, the most
common form of the disease, is characterized by raised, red patches or lesions
covered with silvery white scales of dead keratinocytes. Psoriasis can occur on
the skin of any part of the body (Figure 1.5). Histological features of psoriasis
characteristically
keratinocytes,

show

epidermal

elongation

of

thickening

dermal

due

papillae

or

to

hyper-proliferating

dermal

acanthosis,

neoangiogenesis and immune cell infiltration (Figure 1.5).
Estimated prevalence of psoriasis is around 2% worldwide, but this data comes
from studies from a few populations. A comprehensive study done in the Faroe
Islands reported a prevalence of 2.8% (Lomholt G, 1964) while central Europe
has a prevalence of approximately 1.5 percent (Farber EM et al, 1998). Ethnic
factors have also been implicated in psoriasis. For example, no cases are found
in the Samoan population while a prevalence of 12 percent is noted in Arctic
Kasach’ye (Farber EM et al, 1998). Also in the United States, the prevalence
among blacks (0.45-0.7%) (Kenney JA, 1971) is insignificant compared to the
remainder of the U.S. population (1.4-4.6%) (Christophers E, 2001).
Family studies for psoriasis indicates a genetic predisposition to psoriasis with
albeit unclear inheritance pattern (Henseler T et al, 1985). Population studies
clearly indicate that the incidence of psoriasis is greater among first-degree and
second-degree relatives of patients than among the general population (Farber
EM et al, 1974). In other studies the concordance rate among monozygotic twins
was found to be around 70%, as compared to 20% for dizygotic twins, bringing
further supports for genetic predispositions (Farber EM et al, 1974; Brandrup F et
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Figure 1.5
A

B

Figure 1.5. Macroscopic and microscopic features of psoriatic skin. (A) Characteristic
chronic psoriatic lesions with scaly plaques. (B) Microscopic histology of lesional skin of
psoriasis stained with H&E showing characteristic hyperproliferation of epidermal cells and
dermal acanthosis. (Courtesy: Michel Gilliet, MD)
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al, 1982). In one study almost 71% of children with psoriasis have a positive
family history (Morris A et al, 2001).
There is a well-established notion that the disease course is largely influenced by
environmental factors like seasonal changes (in some patients the symptoms
improve in the summer and worsen in the winter) and physical trauma (local
injuries can trigger exacerbations of the lesions, called Koebner’s phenomenon)
(Eyre RW et al, 1982). Certain drugs have also been found to induce disease
exacerbation but the molecular mechanisms are not fully understood for most of
the reactive flares except a few like beta-adrenergic blockers (decrease intraepidermal cyclic AMP and thereby induce epidermal hyperproliferation) and
lithium (induces proinflammatory cytokine production thereby stimulating immune
cell recruitment to the skin) (Tsankov N et al, 2000). Events of systemic infection
have also been found to induce the disease in some patients. Upper respiratory
tract infection by streptococcas is well recognized as a trigger of psoriasis (Owen
CM et al, 2000). Also exacerbation or even initial manifestation of psoriasis has
been observed in HIV infected patients (Mallon E, 2000). On the other hand there
is gross lack of any report showing infection of the involved skin in psoriasis,
which is conventionally explained by very high expression of endogenous
antimicrobial peptides in the psoriatic epidermis (Davidson DJ et al, 2004).
Pathologic hallmarks of psoriatic lesions are hyperproliferation of keratinocytes,
infiltration of activated T cells in the dermis in situ production of proinflammatory
cytokines (Lowes MA et al, 2007). Gene expression profiling with microarrays in
psoriatic skin samples, compared with uninvolved skin samples or other
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unrelated cutaneous diseases, revealed transcriptome signatures corresponding
to proinflammatory cytokines and chemokines in the lesional skin and molecular
markers signifying dendritic cell activation in nonlesional skin. Several members
of the IL-1 cytokine family as well as IFN-inducible genes are upregulated in
psoriatic lesions of patients (Nomura I et al, 2003; Bowcock AM et al, 2001; Zhou
X et al, 2003). Gene expression studies on the peripheral blood mononuclear
cells collected from psoriatic patients also reveal a differential gene expression
signature when compared to healthy individuals or patients with rheumatoid
arthritis, another autoimmune disorder with involvement of joints (Pascual V et al,
2010). Cluster analysis of the transcripts that were downregulated in these
studies pointed to certain chromosomal regions, that included the psoriasis
susceptibility loci PSORS1 and PSORS2 found through genome-wide linkage
studies (Nair RP et al, 1997). Genes that have been attributed to regulation or
suppression of immune responses in both innate and adaptive axes were found
to be among the downregulated genes in these gene expression studies,
reaffirming the proinflammatory milieu associated in this disease (Pascual V et al,
2010).
Plasmacytoid dendritic cells have been found to be instrumental in initiating the
disease process in psoriasis. PDCs have been found to infiltrate the lesional skin
and type I interferons produced by activated pDCs that populate the lesional skin
have been reported to be very important for the disease initiation. IFNα initiates
the autoimmune-inflammatory a process characterized by the activation of other
immune cells like myeloid DCs, which in turn get matured and stimulate
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pathogenic autoreactive T cells (Nestle et al., 2005). But the specific details of
these mechanisms are not yet fully elucidated.

1.7. Systemic lupus erythematosus: systemic autoimmunity
Systemic lupus erythematosus is a systemic autoimmune disease that presents
with variable symptoms and signs. Diverse combinations of clinical presentations
are seen in SLE patients, like the characteristic butterfly rash on cheek leading to
global rash, arthritis, anemia, thrombocytopenia, serositis, nephritis, seizures and
also psychosis. As a result in the differential diagnosis of patient presenting with
one of these clinical problems SLE is considered, especially in female patients of
15 - 50 years of age, as they are more commonly affected (Rahman A et al,
2008).
SLE has a variable prevalence rate that range from 0.04% among North
Europeans to 0.2% among blacks (Johnson AE et al, 1995). In the United States,
the number of patients with lupus exceeds 250,000. There has been significant
improvement in life expectancy of patients powered by greater understanding of
the pathogenesis and available treatment modalities. While the 4-year survival
rate in the 1950s was reported to be around 50% (Merrell M et al,1955), at
present the 15-year survival rate of lupus patients has reached almost to 80%
(Abu-Shakra M et al, 1995).
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Monozygotic twins show a concordance rate of 25% and which among dizygotic
twins reaches to around 2% (Sullivan KE, 2000), indicating that genetic
predisposition operates but is not sufficient for the disease. Genome-wide scans
among families with multiple affected members have identified a lot of genes that
may take part in lupus pathogenesis (Wakeland EK et al, 2001). Genes for the
MHC molecules, specifically HLA-A1, HLA-B8, and HLA-DR3, have been linked
to lupus pathogenesis (Walport MJ et al, 1982). Null alleles leading to deficiency
of the early complement components C1q, C2, or C4 are taken to be strong risk
factors (Walport MJ, 2002). Genetic loci that promote lupus have also been
identified in mouse models of the disease (Morel L et al, 2000; Wakeland EK et
al, 2001), designated Sle 1, Sle 2, and Sle 3. The genes they contain regulate
immunologic tolerance to nuclear autoantigens, B-cell hyperactivity, and T-cell
dysregulation, respectively (Wakeland EK et al, 2001). The Sle 1 cluster contains
genes homologous to genes in the 1q21–23 and 1q41 regions in human that are
also linked to the human disease. As evident from the examples depicted here, a
lot of the genes found to play a role in the disease pathogenesis encode
components of the immune system, supporting the notion of an autoimmune
pathogenesis.
SLE pathogenesis is characterized by hyperreactive B lymphocytes producing
autoantibodies against self-DNA, chromatin, and RNA-associated proteins that
can be identified in the blood stream. These circulating autoantibodies form
insoluble immune complexes with extracellular host-derived self-nucleic acids
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and get deposited in different tissuebeds like skin, kidney and brain, which in turn
results in local inflammation and tissue damage.
There have been reports that suggest a key role for type I interferons in the
initiation and progression of SLE pathogenesis (Theofilopoulos AN et al, 2005).
Expression of type I IFNs and downstream genes have significant correlation
with the pathogenesis. Type I IFNs drive activation of monocytes that
differentiate into mature dendritic cells, which in turn induce and stimulate
autoreactive B lymphocytes, finally leading to autoantibody production (Blanco P
et al, 2001). Type I IFNs can also enhance B cell receptor signaling (Braun D el
al, 2002). Plasmacytoid dendritic cells (pDCs) are the most efficient producers of
type I IFNs in the body and activation of these cells have been implicated in SLE
pathogenesis. PDCs have been shown to accumulate in tissue lesions and sense
self-DNA contained in immune complexes, which is accompanied by reduction in
their numbers in circulating blood of patients (Cederblad B et al, 1998; Blomberg
S et al, 2001).
According to several recent studies circulating neutrophils also play a key role in
SLE pathogenesis. SLE patients have been shown to have much higher
frequency of apoptotic neutrophils in the circulation. Frequency of apoptotic
neutrophils seems to correlate with the disease progression and the circulating
anti-DNA antibodies (Courtney PA et al, 1999; McConnell JR et al, 2002). Thus
in SLE patients there is a left shift in granulopoiesis as reflected in the circulating
blood with higher numbers of immature neutrophils and gene expression
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signature of granulopoiesis that strongly correlates with expression of type I IFN
genes and disease activity (Bennett L et al, 2003).

1.8. Antimicrobial peptides: old players with new roles
Innate immunity forms a first line of defense against infection by thousands of
potentially pathogenic microorganisms which the multicellular organisms are
continuously exposed to. A group of peptides with antimicrobial activity, present
in even most primitive multicellular organisms and thus showing outstanding
evolutionary conservation, also take part in the innate immune processes. Since
the initial reports of such peptides in plants with antibacterial or antifungal
functions in early 1970s (Fernandez de Caleya R et al, 1972) a lot of similar
peptides has been discovered across the species. A growing interest in these
peptide antibiotics originated from the ever-growing resistance the targeted
pathogens to the conventional antibiotics and the possibilities of therapeutic
applications of these peptides or their synthetic analogues in infectious diseases
(Reddy KV et al, 2004). Most of these peptides have a broad range of
antimicrobial properties, ranging from antibacterial and antifungal activities to
antiviral or anticancer properties in some of them. Moreover over the years they
have been found to directly influence different inflammatory processes, like
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cellular proliferation, wound healing, induction of cytokines and chemotaxis (Bals
R, 2000). Although the antimicrobial peptides are very different in terms of amino
acid composition, peptide length and secondary structure, most of them exert the
antimicrobial effects by interaction with and disruption of the microbial cell
membrane leading to cell death. Different mechanisms that these peptides take
to kill microbial pathogens have been proposed such as, inhibition of membrane
protein synthesis (Engstrom P et al, 1984; Axen A et al, 1997), interference with
stress response (Groisman EA et al, 1996), inhibition of DNA synthesis (Boman
HG et al, 1993), production of hydrogen peroxide (Leem JY et al, 1996).
Cathelicidin is a group of antimicrobial peptides containing a conserved signal
sequence and a pro-region showing homology to cathelin, a cathepsin L inhibitor,
while C-terminal domain shows no conservation (Hancock RE et al, 2000). LL37
is the only human cathelicidin characterized till date. LL37 is small peptide
composed of 37 amino acids with a linear structure. Final LL37 peptide forms by
cleavage of the C-terminal end of the human CAP18 protein (hCAP18) (Cowland
JB et al, 1995; Gudmundsson GH et al, 1996). LL37 has been shown to adopt a
random coil structure in a hydrophilic milieu and an alpha-helical conformation in
a hydrophobic environment (Turner J et al, 1998).
LL37 is expressed in monocytes, neutrophils, T and B lymphocytes, NK cells and
epithelial cells in different parts of the body like skin, testis, gastrointestinal and
respiratory tracts (Cowland JB et al, 1995; Gudmundsson GH et al, 1996; Frohm
M et al, 1997; Bals R et al, 1998).
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Both Gram positive and Gram negative bacteria has been shown to be
susceptible to the antimicrobial activity of LL37 (Turner J et al, 1998). LL37 has
also been shown to have chemotactic activity for neutrophils, monocytes, mast
cells and T cells.
The concentration of LL37 in the body differs among different physiological
condition and pathological contexts. For example according to some reports
concentration of LL37 in adult sweat is around 1 uM. In the bronchoalveolar
lavage fluid of infants also LL37 reaches similar concentrations (Davidson DJ et
al, 2004). On the other hand in the context of infections or inflammation
expression of this peptide in neutrophils, keratinocytes and in other epithelial
cells is enhanced by several folds (Dorschner RA et al, 2001). An example very
appropriate for our studies is the cutaneous autoimmune disease psoriasis,
where LL-37 concentration in the lesions have been reported to reach a median
value of 304 uM (Davidson DJ et al, 2004).
A shared property of most of the antimicrobial peptides described so far is found
to be a tendency to adopt an amphipathic conformation with clusters of
hydrophobic and cationic amino acids positioned in different spaces of the
molecules. The fact that bacterial cell wall is sensitive to these peptides is
attributed to a very high content of anionic phospholipid moieties in the outer
membrane leaflet of the bacterial cell wall. This is in stark contrast with the outer
membrane of cells rich in electro-neutral lipids in higher organisms conferring a
relative specificity for the antimicrobial action of these peptides (Ganz T, 2002). A
study on bacterial infections with Shigella reported an interesting observation of
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an inhibition of AMP expression, which was mediated by the plasmid released by
the bacteria (Islam D et, 2001). Another study reported that LL-37 can bind to
plasmids and target them to the nuclear compartment of mammalian cells
followed by the expression of those plasmids (Sandgren S et al, 2004). These
studies, along with the cationic amphipathic domains of LL37 molecule and the
observation that LL37 is overexpressed in the psoriatic skin lesions led to the
previous study of our group where Lande R et al found that LL37 can bind to
human DNA and target it to the endosomal compartment in the plasmacytoid
dendritic cells leading to their activation through toll-like receptor 9 (Lande R et
al, 2007). Thus apart from contributing to innate immune response by direct
killing of microorganisms other facets of innate immune function of the
antimicrobial peptides has become an interesting area of study.

37

2. Description of the research study
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2.1. Chapter 1: Antimicrobial peptide LL37 binds self ribonucleic
acids and forms particulate complexes
2.1.a. Background and Rationale:

Role of plasmacytoid dendritic cells (pDCs) in the pathogenesis of autoimmune
inflammation has been studied in different clinical contexts. The characteristic
endosomal toll-like receptors (see section 1.4) in the pDCs that can recognize
nucleic acid molecules and a very efficient intracellular signaling machinery for
induction of type I interferon gene expression and secretion of these cytokines,
equip this subset of dendritic cells with the ability to respond to microbial
challenge by producing very high amounts of type I interferons, thus earning
them the name professional type I interferon producing cells (see section 1.2).
Type I interferon plays a great role in driving antiviral immunity making pDCs the
key immune cells in combating such infectious challenges. The discrimination of
microbial nucleic acids from self nucleic acids by these TLRs in pDCs (see
section 1.4) is conventionally explained by recognition of structural changes in
the nucleic acid molecule that differentiate between the molecules in lower
organisms from higher organisms. But it has also been shown that endosomal
seclusion of the receptors play a vital role in the discrimination process as self
nucleic acid can not normally get access to these intracellular compartments
(discussed in section 1.4). It has been shown by previous studies in systemic
lupus erythematosus (SLE) that self nucleic acids in complex with respective
autoantibodies do access the endosomal compartments of pDC via FcγRII-
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mediated endocytosis (Ronnblom L et al, 2003; Means TK et al, 2005; Barrat FJ
et al, 2002). Ensuing pDC activation and production of type I IFNs drives the
autoimmune pathogenesis in SLE. This notion has been supported by studies on
murine models of SLE in TLR7 or TLR9 deficient mice (Christensen SR et al,
2006; Leadbetter EA et al, 2002), and also by a study that showed TLR7 gene
duplication induces a lupus-like disease in mouse (Deane JA et al, 2007).

Previous studies done in our lab by other investigators had revealed an
instrumental role of pDC-derived IFNα in the initiation of the disease process in
the cutaneous autoimmune disease psoriasis (Nestle FO et al, 2005).
Assessment of fractionated skin extracts from psoriatic skin to activate pDC
cultures revealed a fraction containing the antimicrobial cathelicidin LL37 to be
able to achieve that (Lande R et al, 2007). This study found that LL37 peptide
can bind to self DNA molecules through an electrostatic interaction between the
anionic nucleic acid molecules and the cationic peptides forming complexes.
These complexes then are taken up by pDCs into the endosomal compartments
where they trigger TLR9 activation resulting in type I IFN production (Lande R et
al, 2007). As discussed in the section 1.6, psoriatic skin is known to have a very
high expression of endogenous antimicrobial peptides and this fact was cited to
explain lack of infections involving psoriatic skin. But Lande R et al showed a
new role of the antimicrobial peptide in breaking the innate tolerance of self DNA
and activating innate immune cells. The hypothesis implied from these findings
was that self nucleic acids extracellularly released by host cell death can bind
this antimicrobial peptide when it is around and then get access to the
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endosomal compartments in pDCs to trigger TLR activation. Very high cell turnover in the epidermis and resulting release of self nucleic acids and associated
high expression of antimicrobial peptides in psoriasis thus predisposes this
clinical condition to such innate immune activation. DNA molecules are relatively
less susceptible to fast extracellular degradation than RNA molecules and thus
seem to fit into the hypothesis convincingly. Thus access of the host-derived
nucleic acids to the relevant TLRs in the host cell can lead to the break of innate
tolerance to them and autoreactivity.

To confirm that the antimicrobial peptide LL37 can really enable pDCs to sense
native self nucleic acids released by dying cells, we tried to simulate the
condition in vitro. U937 cells, a human cell-line, were subjected to secondary
necrotic process by UV-irradiating the cells and then incubating them overnight at
37oC. PDCs were stimulated with supernatants of these UV-irradiated cells,
which undergo apoptosis and secondary necrosis and release self-nucleic acids
(Lovgren T et al, 2004). These supernatants induced significant amount of IFN-α
in pDCs when mixed with LL37 but not when given alone (Figure 2.1), thus
confirming ability of LL37 to bind nucleic acids released by cell death and taking
them inside pDC endosomes. But interestingly, depletion of DNA from the
supernatants by treating the supernatant with DNase could inhibit IFN-α induction
only partially but not completely (Figure 2.1). That created the possibility that
other elements released by the dying cells (possible other nucleic acid species)
can also bind to the peptide and work in the same way. Depletion of RNA from
the supernatants by treating them with RNase also leads to partial inhibition,
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Figure 2.1

Figure 2.1. Both DNA and RNA released during cell death can activate pDCs in the
presence of LL37. IFN-α produced by pDCs after stimulation with supernatants from dying
(UV-irradiated) U937 cells, either alone or premixed with LL37. In some experiments, DNA
and/or RNA was depleted from supernatants of dying cells by pretreatment with DNase I
(2,000 U/ml) and/or RNase A (50 µg/ml). Data are the mean ± SEM of four independent
experiments. *p value <0.05, paired Student’s T test. ns = not significant.
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while the combined depletion of RNA and DNA completely abolished IFN-α
induction (Figure 2.1). These results indicated that not only self-DNA released
by host cell death, but also self-RNA released simultaneously, despite its
extreme susceptibility to nuclease degradation, can contribute to the pDC
activation in presence of LL37 peptide. These findings led to the present study
investigating whether these cationic antimicrobial peptides can bind to ribonucleic
acid molecules in the same manner as they bind to DNA and what are the
implications of this interaction.

2.1.b. Materials and Methods:
Reagents.
The synthetic human antimicrobial peptide LL37 (amino acid sequence:
LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES),

the

corresponding

scrambled peptide GL37 having same amino acids in different sequence (amino
acid sequence: GLKLRFESKIKGEFLKTPEVRFRDIKLKDNRISVQR) and Tamralabeled LL37 were purchased from Innovagen, Lund, Sweden. LyoVec-free
single stranded 40 base long phosphothioate linked RNA sequences named
ssRNA40

(5’-GsCsCsCsGsUsCsUsGsUsUsGsUsGsUsGsAsCsUsC-3’,

‘s’

denotes phosphothioate linkage) was from Invivogen, CA and used at a final
concentration of 5 µg/ml. Ribogreen RNA quantitation kit was purchased from
Molecular Probes, CA. The Ulysis Nucleic Acid Labeling Kit for Alexa 488
fluorophore labeling of nucleic acids was from Molecular probes, CA.
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Isolation of nucleic acids.
Total human RNA (self-RNA) and genomic DNA (self-DNA) were extracted from
cell lines or inflammatory skin samples using standard procedures. In brief, cells
were homogenized in Trizol reagent (Invitrogen), followed by phase separation
with chloroform. RNA was precipitated from the aqueous phase by isopropanolol
(Sigma Aldrich) and was washed in 75% ethanol. DNA was precipitated from the
interphase and the organic phase with ethanol followed by wash in 0.1M sodium
citrate (Sigma Aldrich) in 10% ethanol.

Nucleic acid condensation assay
Ability of the LL37 peptide to bind to ribonucleic acid was assessed by a
spectrophotometric assay using the RNA-binding dye Ribogreen. 10 µM LL37
peptide was added with 5ug/ml U937 RNA in a volume of 20 µl (volume made up
by nuclease free water) and was incubated at room temperature for 20 min. The
dye Ribogreen for a final dilution of 1:20 (5 µ in 80 µl) was added in TE buffer.
80µl of the TE buffer with the dye was added to the 20 µl of the nucleic acidpeptide suspension, mixed well and put in a cuvette to measure fluorescence in
500nm to 600nm emission wavelength range in a Jasco FP-6300 spectrofluorometer (Jasco Inc., Easton, MD). The data was analyzed on a Jasco Spectra
Manager software.
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Generation of nucleic acid-LL37 complexes.
10 µg of the antimicrobial peptide LL37 or the scrambled peptide GL37 were
added with 1 µg of self-RNA or self-DNA in 20 µl of PBS. To look for nucleic acid
complexes in the culture supernatant of necrotic cells, U937 cells were UVirradiated (480 mJ/cm2 for 30 min) in a UVP TL-2000 ultraviolet crosslinker (UVP,
LLC, Upland, CA), washed and then resuspended in complete medium to be
cultured overnight (50×106/ml) for inducing secondary necrosis. After harvesting
the supernatant by spinning down the necrotic cells at 3000 rpm for 5 min, 100 µl
of the supernatant was added with 10 µg of LL37. The supernatant added with
LL37 was then incubated at room temperature for 30 min and then spun down to
collect the pellet. The pellet was the resuspended in 20µl PBS. Ribogreen
(Molecular Probes, CA), a nucleic acid-binding dye sensitive

to low

concentrations of RNA, was diluted with PBS. To visualize the RNA and DNA
complexes the suspensions were added with 1:10000 Ribogreen and 0.1 ng/ml
DAPI (Sigma-Aldrich, MO) respectively and incubated at room temperature for 10
min. 5 ul of the suspension was put on a glass slide, covered with a cover slip
and visualized by confocal microscopy. In some experiments the supernatant of
the necrotic cells after harvesting were first treated with DNase I (200U/ml),
RNase A (10µg/ml) or both together for 1 h at 37o C, and then were added with
LL37, to differentiate between and quantitate the RNA and DNA particles being
formed in presence of the LL37 peptide.
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Fluorescence resonance energy transfer.
Self-RNA was labeled with Alexa 488 fluorophore using the Ulysis Nucleic Acid
Labeling Kit according to manufacturer’s instruction. Labeled self-RNA (1 ug)
was added with Tamra-labeled LL37 (10 ug, procured from Innovagen, Sweden)
in a volume 20 ul made with PBS. 5 ul of this nucleic acid-AMP suspension was
put on slide, covered with a coverslip and sealed. Image was acquired on a Leica
TCS SP2 confocal microscope using 488 nm and 543 nm lasers working in a
sequential scanning scheme. Fluorescence resonance energy transfer (FRET)
was analyzed based on donor recovery after acceptor photobleaching.
Fluorescence intensity of Alexa 488 in selected complexes was imaged at the
488 nm excitation and 496-535 nm emission. TAMRA was photobleached by
illuminating a rectangular area (shown in the first panel) with the 543 laser at the
maximum power (160 scans), and the complexes were imaged again for Alexa
488 using the same settings. The extent of TAMRA photobleaching was about
80%. FRET analysis was done using the SlideBook 4.2 software (3I, Denver).
The calculated FRET efficiency was 96.5% based on the equation E=(DpostDpre)/Dpost, where Dpre and Dpost are average donor intensities in the areas before
and after acceptor photobleaching.
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Scanning electron microscopy.
50 µg of the peptides LL37 was mixed with 5 µg of self-RNA or ssRNA40 (used
as uniformly sized control RNA molecule) in 100 µl of PBS. The self-RNA-LL37
and ssRNA40-LL37 complex suspensions were then taken to High Resolution
Electron Microscopy Core Facility at the MD Anderson Cancer Center for
scanning electron microscopy. At the core facility the suspensions of the nucleic
acid-peptide

complexes

were

air-dried

overnight

on

poly-l-lysine-coated

coverslips and then the samples were mounted on to double-stick carbon tabs
(Ted Pella Inc., CA), which have been previously mounted on to aluminium
specimen mounts (Electron Microscopy Sciences, PA). The samples were then
coated under vacuum using a Balzer MED 010 evaporator (Technotrade
International, NH) with platinum alloy for a thickness of 25 nm. It was followed by
a flash carbon coating. Samples were examined in a JSM-5910 scanning
electron microscope (JEOL USA Inc., MA) at an accelerating voltage of 5kV.

Particle size estimation:
To assess the size distribution of the nano-scale particles formed by the selfRNA-LL37 complexes we used a particle-sizing instrument Zetasizer Nano
(courtesy Malvern Instruments Ltd, Worcestershire, UK) that works based on
dynamic light scattering from the particles in suspension. RNA-LL37 complexes
were prepared with both self-RNA isolated from U937 cell line and a uniformly
sized 40 nt long short sequence of RNA called ssRNA40, which is a TLR7/8
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agonist. 100 µl of the suspensions in PBS were made with adding 5 µg of RNA
with 50 µg of LL37. Then volume was made to 1 ml in these suspensions with
additional PBS and after vortexing the particle size distribution was quantitated in
the Zetasizer Nano instrument. The data was analyzed in Zetasizer software
provided by Malvern Instruments.

Nuclease protection assays.
10 µg of the peptides LL37 or GL37 were mixed with 1 µg of self-RNA or selfDNA in 20 µl of double distilled water. This suspension containing the RNA-LL37
complexes was then left at room temperature for 30min and then incubated for
different time-points with 50 µg/ml RNase A at 37°C. Then RNA in the
suspensions was quantitated using the fluorometric Ribogreen RNA Assay Kit
(Molecular probes, CA). In short, the dye Ribogreen for a final dilution of 1:20 (5
µ in 80 µl) was added in TE buffer. 80µl of the TE buffer with the dye was added
to the 20 µl of the nucleic acid-peptide suspension, mixed well and put in a
cuvette to measure fluorescence in 500nm to 600nm emission wavelength range.
To visualize the RNA and the RNA-peptide suspension and effect of RNase on
them in an agarose gel, the naked RNA and the RNA complexes were run on a
1% agarose gel (with 0.005% ethidium bromide). The gel was imaged in a UV
transilluminator gel imager (Biorad Laboratories, CA).
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2.1.c. Results & Discussion:
Antimicrobial peptide LL37 binds and condenses self-RNA molecules.
To investigate whether host-derived RNA can interact with the antimicrobial
peptide LL37 to form characteristic complexes similar to DNA we used a
fluorometric assay using the nucleic acid binding fluorophore Ribogreen (Jones
LJ et al, 1998). Self-RNA alone or added with LL37 was quantitated using this
assay. Ribogreen reagent binds naked RNA molecules and the bound
fluorophore when illuminated with 488 nm light source gives fluorescence in the
range 525nm to 530nm. But if the LL37 peptides bind to and condenses RNA the
fluorophore is not able to access the as many binding sites as it would have done
if given to naked RNA molecules (Figure 2.2.A). Thus the fluorescence detected
is diminished. We found that presence of LL37 with self-RNA greatly diminished
the Ribogreen fluorescence (Figure 2.2.B). With increasing concentration of the
peptide there was greater reduction in fluorescence revealing 10 uM peptide
concentration to be optimal for the condensation and binding.

Self-RNA-LL37 complexes are visible under microscope.
Interestingly, when self-RNA purified was added with LL37 to make the
complexes we observed formation of particulate precipitates at the bottom of the
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Figure 2.2

A

B

Figure 2.2. LL37 can bind to self ribonucleic acid molecules and condense them. (A)
Schematic representation of the principle of the fluorometric assay with the RNA-binding
dye Ribogreen to assess peptide binding to RNA molecules and resulting condensation
leading decrease in Ribogreen binding and fluorescence. (B) Indicated amounts of LL37
peptide was incubated with self-RNA (10 µg/ml) for 30 min and then a fluorometric assay
was done with the RNA-binding dye Ribogreen. Data representative of multiple
experiments.
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culture wells ranging in size from 1−30 µm (Figure 2.3.A). But addition of GL37,
a scrambled form of the peptide with the same amino acid composition but with a
different sequence, did not form these particulate complexes. On fluorescence
microscopy the visible particulate complexes fluoresced when stained with
Ribogreen (stains RNA preferentially, but also DNA) but not with DAPI (stains
DNA exclusively) showing they contained RNA (Figure 2.3.B). Self-DNA when
complexed with LL37 also formed these particles and they could be stained with
DAPI (Figure 2.3.B).
We wanted to see whether similar particles also form in the supernatants
collected from the dying cells undergoing secondary necrosis when added with
the LL37 peptide. When added with LL37 but not GL37, the supernatants of
dying U937 cells also formed similar particulate complexes. A large number of
these complexes contained RNA as they stained as Ribogreen+ DAPI- (Figure
2.3.B) and because these particles were not seen with RNase pretreatment of
the supernatants to specifically deplete free RNA (not shown). Number of visible
RNA particles was more than DNA particles, identified as DAPI+ particles (Figure
2.3.B). Predominance of RNA particles in the supernatants from necrotic cells is
supported by the fact that mammalian cells contain much more RNA than DNA
(Kariko K et al, 2005). When imaged in high magnification these RNA-LL37
complexes had a characteristic morphology with aggregation and branching of
bead-like structures (Figure 2.3.C).
To prove that these microscopically visible particulate complexes indeed form by
molecular interaction between RNA and LL37 we used a fluorescence resonance
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Figure 2.3
A

B

C

Figure 2.3. LL37 binds self-RNA and forms aggregated particles. (A) Characteristic
particle formation in culture plates by self-RNA and LL37 as seen under a light microscope
at 40X. The scrambled peptide GL37 fails form such complexes. (B) Confocal microscopy
images of self-RNA–LL37 and self-DNA–LL37 complexes generated in vitro (top panels) or
formed by mixing supernatant of dying U937 cells with LL37 (bottom panels) and stained
with Ribogreen (which stains both RNA and DNA) and DAPI (which stains DNA exclusively).
RNA and DNA complexes were detected as Ribogreen+/DAPI- and Ribogreen+/DAPI+
complexes, respectively. Bar, 20 µm. (C) Complexes formed by Alexa 488-labeled self-RNA
and the LL37 peptide showing characteristic branched aggregation of bead-like structures.
Imaged in confocal microscope, bar=5µm.
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Figure 2.4

Figure 2.4. The microscopically visible complexes form by molecular interaction
between self-RNA and LL37. Confocal microscopy of self-RNAAlexa488–LL37 (top left panel)
and self-RNA–LL37Tamra (bottom left panel), or self-RNAAlexa488–LL37Tamra complexes (right
panels). Self-RNAAlexa488–LL37Tamra complexes did not appear in the green channel after
excitation at 488 nm (top right quadrant) but did appear in the red channel (top left
quadrant), suggesting FRET. Photobleaching of the red fluorophore TAMRA with the 543
laser (bottom left quadrant) resulted in recovery of green fluorescence of the Alexa Fluor
488 fluorophore in response to excitation at 488 nm (bottom right quadrant). Numbers on
the top of the right panels indicate excitation/emission wavelength. Size-bars: (left panels)
20 µm; (right panels) 10 µm.
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energy transfer (FRET) experiment using the efficient donor-acceptor pair of
Alexa 488 and Tamra fluorophores to do the FRET imaging. Human RNA labeled
with fluorescent dye Alexa 488 (self-RNAAlexa488) and Tamra-labeled LL37
(LL37Tamra) were added together to generate the complexes. Excitation of these
self-RNAAlexa488/LL37Tamra complexes at 488 nm failed to elicit green fluorescence
but gave a red fluorescence due to efficient transfer of the energy imparted on
the Alexa 488 fluorophores to Tamra, as the emission spectrum of Alexa 488
(500-620nm) overlap considerably with the excitation spectrum of Tamra (450600nm) (Figure 2.4). On the other hand, after photobleaching of the Tamra
fluorophore at 543 nm in a selected area of a complex, excitation at 488 nm
could induce the green fluorescence from that area of the complex,
demonstrating a FRET efficiency of over 90%. A FRET efficiency of this
magnitude points to a close molecular proximity between RNA and LL37 or in
other words these two entities bind to each other to form these particulate
complexes.

The particles formed by self-RNA-LL37 complexes are micro-aggregates of
nano-scale particles.
Further analysis of the RNA complexes by scanning electron microscopy,
revealed that they consisted of aggregates of smaller electron-dense nano-scale
particles. With total human RNA (self-RNA) the particles were more pleomorphic
that may result from different sizes of the individual RNA molecules in that
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Figure 2.5
A

B

Figure 2.5. Self-RNA-LL37 complexes are composed of micro-aggregates of nanoscale particles. (A) Scanning electron microscopy of RNA–LL37 complexes formed by selfRNA fragments (top panels) or the short ssRNA sequence ssRNA40 (bottom panels). Bars:
(left panels) 10 µm; (right panels) 1 µm. (B) Particle size distribution of self-RNA-LL37 (top)
and ssRNA40-LL37 complexes.

55
sample. With the uniformly sized short RNA sequence ssRNA40 the complexes
showed more uniform particle sizes. By visual estimation from the SEM images
we found the sizes of the particles ranging from 100 nm to 700 nm when total
human RNA was used and ranging from 100 to 300 nm when short singlestranded RNA sequences were used (Figure 2.5.A).
Particle sizing experiments on a Zetasizer instrument also revealed a similar size
range for the particles. The sizes ranged from 100−900 nm with self-RNA and
100−300 nm when short single-stranded RNA sequences were used (Figure
2.5.B).

The electrostatic interaction between LL37 and RNA results in the
particulate complexes.
The complex formation between the anionic ribonucleic acid molecules and the
cationic peptide LL37 suggests an electrostatic interaction between the two
molecular entities. LL37 has previously been shown to interact with human
deoxyribonucleic acid in the same manner and the resulting complexes were
found to be dissolved on increasing the ionic strength of the suspension by
adding sodium chloride solution. In our experiments also the self-RNA-LL37
particles were rapidly dissolved by addition of sodium chloride, indicating that
ionic interactions between the cationic peptide and the negatively charged
phosphate groups of the nucleic acid are involved in the complex formation
(Figure 2.6). While lower strengths of the salt solution could not achieve this
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Figure 2.6

Figure 2.6. Self-RNA-LL37 complexes form by electrostatic interaction between the
anionic nucleic acid molecule and the cationic peptide. Number of self-RNA–LL37
complexes counted as visible precipitates by phase-contrast microscopy. Increasing
concentrations of NaCl (10, 50, 100, 200, 500, and 1,000 mM) were used to dissolve the
complexes. Data are representative of three independent experiments.
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dissolution, at higher concentrations (>500mM) could reverse the electrostatic
interaction between nucleic acids and the peptide and the particles dissolved.

Self-RNA-LL37 particles are protected from enzymatic degradation.
Free RNA is exquisitely sensitive to degradation by extracellular RNases. Thus
self-RNA, even if released extracellularly by the dying cells may not be available
for a long time for immune cells to take them up. Efficient extracellular nucleases
work toward clearing the extracellularly released nucleic acids. But the
electrostatic interaction of RNA with the LL37 peptide and resulting condensation
of the RNA molecules creates a possibility of protection of these condensed
particles from the extracellular enzymatic degradation. To test whether LL37 can
protect self-RNA from nuclease activity, self-RNA-LL37 complexes, self-RNA
alone or self-RNA mixed with the control peptide GL37 were treated with RNase
A and RNA was quantitated by a fluorometric assay using the RNA-sensitive dye
Ribogreen at different time-points. As expected RNA alone and RNA mixed with
GL37 were rapidly degraded after treatment with RNase A. But the self-RNALL37 complexes were found to be resistant to this degradation (Figure 2.7.A).
This ability of LL37 to protect RNA from RNase degradation was also confirmed
in an agarose gel electrophoresis-based nuclease protection assay. Self-RNA
alone or in complex with LL37, with or without a treatment with RNase A, were
run on a gel and we found that self-RNA, when in complex with LL37 was
retained in the loading wells and was protected from digestion by RNase (Figure
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Figure 2.7

Figure 2.7. Self-RNA–LL37 complexes are protected from enzymatic degradation. (A)
Self-RNA alone, self-RNA–LL37 complexes, or self-RNA mixed with the control peptide
GL37 were treated with RNase A and quantified over 60 min by a fluorometric assay. The
percentage of protection was calculated as the ratio of remaining RNA over the initial RNA
input. Data are representative of at least three experiments. (B) Agarose gel electrophoresis
of self-RNA alone and self-RNA–LL37 complexes before and after RNase A treatment
visualized by ethidium bromide staining.
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2.7.B). Retention of the complexes in the wells may result from neutralization of
the anionic charge on the RNA molecules due to the electrostatic interaction with
the cationic peptide and also due to greater mass of the RNA complexes
compared to RNA alone. The condensed structure of the

self-RNA-LL37

complexes may prevent the enzymes to access the cleavage sites of the RNA
molecules resulting in the protection. Thus, LL37 condenses RNA to form
compacted particles, which are highly protected from extracellular degradation.

60

2.2. Chapter 2: Self-RNA-LL37 complexes activate dendritic cells
through endosomal toll-like receptors
2.2.a. Background and Rationale

In our studies, as described in Chapter 2.1, we found that the endogenous
antimicrobial peptide LL37 can interact with human ribonucleic acid molecules
based on electrostatic interaction of the cationic domains on the peptide and
anionic nucleic acid molecule. Previous studies done in our lab had found LL37
as a key molecule expressed in the psoriatic skin that can bring about activation
of the plasmacytoid dendritic cells resulting in type I IFN production (Lande R et
al, 2007). LL37 was found to make complexes with human DNA and these DNALL37 complexes were then internalized into the pDCs to trigger activation of
TLR9, the DNA-recognizing TLR present in pDC endosomes (see Sections 1.6 &
1.8; Lande R et al, 2007). Similar involvement of host-derived RNA in the
activation of pDCs was plausible given the endosomal expression of TLR7 in
pDCs that can recognize RNA molecules. But access of extracellularly released
self-RNA to the pDC endosomes was physiologically somewhat improbable
given the exquisite susceptibility of RNA molecules to extracellular enzymatic
degradation. But we found that the condensation of RNA molecules resulting
from electrostatic interaction with LL37 rendered them significantly resistant to
enzymatic digestion and thus fuelled the probability of self-RNA molecules being
able to access the endosomal TLRs in pDCs and contributing to the autoreactive
innate immune activation.
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Psoriatic skin shows early pDC infiltration and the chemokine Chemerin is
overexpressed in early psoriatic lesions and has been implicated in the
recruitment of pDCs (Albanesi C et al, 2009). PDC-derived type I interferons
have been shown to be instrumental for the initiation of the disease (Nestle FO et
al, 2005). But it has also been shown that psoriasis is essentially a T-cell
mediated disease and there is involvement of myeloid DCs. The pDC activation
in response to DNA-LL37 complexes induce very potent type I IFN production but
fails to drive maturation of these dendritic cells to be able to express the
costimulatory molecules, produce other proinflammatory cytokines and finally to
induce T cell activation by autoreactive priming (Lande R et al, 2007). MDCs
have also been shown to infiltrate the lesional skin in psoriasis and there are
obvious reasons to believe that these mDCs drive the T cell activation in
psoriasis. MDCs do have endosomal TLRs that can recognize nucleic acids but
they are specific for RNA molecules (TLR3 for dsRNA and TLR8 for ssRNA).
DNA recognizing TLRs are not present in mDC endosomes. Ability of LL37 to
bind self-RNA and protect them from extracellular enzymatic degradation may
enable the RNA molecules to access the endosomal compartments in both pDCs
and mDCs, thus providing a potential mechanistic explanation for mDC activation
in psoriasis.

In light of these possibilities we did experiments to find out whether the self-RNALL37 complexes can access the endosomal compartments of the dendritic cells
and if they can whether they are able to activate the DCs by triggering toll-like
receptors.
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2.2.b. Materials and Methods
Reagents.
LyoVec-free

single

stranded

RNA

sequences

GsCsCsCsGsUsCsUsGsUsUsGsUsGsUsGsAsCsUsC-3’,

ssRNA40
‘s’

(5’-

denotes

phosphothioate linkage) and ssPolyU (single-stranded poly-uridine) were from
Invivogen, CA and used at a final concentration of 5 µg/ml. TLR9 agonist
oligonucleotide CpG-2006 (5'-tcgtcgttttgtcgttttgtcgtt-3') was produced by Trilink
(San Diego, CA) and used at a final concentration of 1 µΜ. Synthetic TLR7
agonist R837 (final concentration used 1 µM) and TLR8 agonist R848 (final
concentration used 100 ng/ml) were from Invivogen, CA. The specific human
TLR7

oligonucleotide

antagonist

C661

and

the

corresponding

control

oligonucleotide sequence (ctrl-ODN, 5'-tcctgcaggttaagt-3') were kindly provided
by Dr. Franck Barrat from Dynavax Corporations, CA and they were used at a
final concentration of 1 µM to pre-treat pDC for 30min at 37°C before stimulation.
The endosomal acidification inhibitor Bafilomycin A1 from Streptomyces griseus
was purchased from Sigma-Aldrich (St. Louis, MO).

Isolation of nucleic acids.
Total human RNA (self-RNA) and genomic DNA (self-DNA) were extracted from
cell lines or inflammatory skin samples using standard procedures as described
in the section 2.1.b. Skin samples from patients with Psoriasis vulgaris, Atopic
dermatitis and healthy individuals were taken by 6-mm punch biopsies as
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previously described (27), under approved protocols at the M. D. Anderson
Cancer Center in Houston and the Heinrich-Heine University in Dusseldorf.

Isolation and generation of pDCs and mDCs.
Use of human blood cells for this study was approved by the Institutional Review
Board for Human Research at the M.D. Anderson Cancer Center. PDCs were
isolated from buffy coats of healthy volunteers. In short peripheral blood
mononuclear cells (PBMCs) were isolated from the buffy coats by centrifugation
on Ficoll-Paque (GE Healthcare, Uppsala, Sweden). PDCs were enriched from
the PBMCs by magnetic immuno-selection with anti-BDCA-4 microbeads
(Miltenyi Biotec, CA) and were the sorted by FACS Aria (BD Bioscience, CA)
according to their lineage− CD11c− CD4+ CD123+ phenotype. Immature myeloid
DCs were generated from blood monocytes. Monocytes were first obtained from
PBMC by magnetic immuno-selection using anti-CD14 microbeads (Miltenyi
Biotec) and cultured for 5 days with GM-CSF and IL-4 (both at 100ng/ml, from
R&D Systems, CA). Circulating conventional DCs were isolated from PBMC by
magnetic immuno-depletion of B cells with anti CD19 microbeads, followed by
magnetic immuno-selection using anti-CD1c microbeads (Miltenyi Biotec). All the
primary cell cultures were done in RPMI 1640 medium added with 10% fetal calf
serum, 10mM HEPES buffer, 1mM sodium pyruvate and penicillin-streptomycin
antibiotic cocktail. Primary pDCs were cultured and stimulated in round bottom
96 well plates while myeloid DCs were cultured in flat bottom plates.
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Stimulation and analysis of pDC and mDC.
Suspensions containing RNA-LL37 or DNA-LL37 complexes made in 20 µl
volume of PBS or 100 µl of supernatants of dying cells were added to pDC and
mDC cultures in a final volume of 200 µl in RPMI 1640 medium with 10% fetal
calf serum. Stimulations with the positive controls were done using CpG-2006 for
TLR9, R837 for TLR7, R848 for TLR8 and Poly I:C for TLR3. We used
Bafilomycin (Sigma-Aldrich, MO), a vesicular proton pump inhibitor, to inhibit
endosomal acidification and TLR activation. To inhibit TLR7 we used C661, a
specific oligonucleotide provided kindly by Dr. F.J. Barrat from Dynavax
Technologies, CA. After overnight stimulation with indicated stimuli, supernatants
of pDCs and mDC cultures were harvested. Production of IFN-α (PBL Biomedical
Laboratories), IL-6 and TNF-α (R&D Systems) in the supernatants were
measured by ELISA. The stimulated pDCs and mDCs were also stained with
fluorochrome-labeled anti-CD80, anti-CD86 and anti-CD83 antibodies (BD
Pharmingen, CA) for analysis by flow cytometry. In some experiments myeloid
DCs were primed with supernatant from pDCs cultures activated by self-DNALL37 before stimulating the mDCs with self-RNA-LL37 complexes. The pDC
supernatants used in these experiments were sometimes added with a
combination of anti-human IFN-α (104 U/ml), anti-human IFN-β (2×103 U/ml)
antibodies and anti-human IFN-αβ receptor antibody (clone: MMHAR-2, 10
µg/ml) before adding to the mDC cultures (all these antibodies were from PBL
Biomedical Laboratories, NJ).
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Uptake of LL37–human-RNA complexes in pDCs and mDCs.
To assess the internalization of the self-RNA-LL37 complexes we used RNA
labeled with Alexa 488 fluorophore. PDC or mDC cultures were added with selfRNAAlexa488 alone or Self-RNAAlexa488-LL37 complexes. After 4 h of incubation at
37oC, the cells were harvested, and after washing with FACS buffer (PBS with
2% human serum and 0.5 mM EDTA) were analyzed by flow cytometry. To
confirm entry of the complexes inside the cell we did confocal microscopy of the
DCs after adding Self-RNAAlexa488-LL37 complexes in culture. After 4 h of
incubation, cells were stained with Alexa 647-conjugated anti-HLA-DR
(BioLegend, CA) and the slides were mounted in Prolong Gold antifade mounting
media (Molecular Probes. CA). A Leica TCS SP2 confocal microscope was used
to acquire the images, which was then analyzed with the Leica confocal software.

Luciferase reporter assay.
Transient transfection was done in HEK293T cells with 500 ng of TLR3-GFP or
TLR8-HA expression vectors (both from Invivogen, CA) and 100 ng of NFkBluciferase reporter plasmid. Transfection was done with lipofection using Fugene
6 (Roche Applied Science, IN). The plasmids (indicated amounts) were added
with Fugene 6 (3 µl) in final volume of 50 µl serum-free Opti-Mem I medium
(Invitrogen, CA) and 250 X 103 cells/well in 6-well plates were transfected.
Simultaneous transfection of 5 ng Renilla luciferase reporter gene (pRL-TK) was
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used as an internal control for transfection efficiency. After overnight incubation
the transfected cells were collected, plated 50 X 103/well in a 24 well plate and
stimulated as indicated for another 24 h. Poly I:C and ssPolyU complexed with
cationic lipids (DOTAP, from Roche Applied Science, IN) were used as positive
controls for activation of TLR3 and TLR8 respectively. Luciferase activity was
measured with a dual-luciferase reporter assay system (Promega Corp., WI).

2.2.c. Results & Discussion:
Self-RNA can induce IFN-α production by plasmacytoid dendritic cells in
complex with LL37.
To investigate whether the complexes formed by self-RNA with LL37 can activate
plasmacytoid dendritic cells similar to self-DNA as described in previous studies,
pDCs were stimulated with total human RNA (self-RNA) extracted from U937
cells in complex with LL37. Self-RNA induced IFN-α production in a dosedependent manner when in complex with LL37 but it failed to do the same when
given to the pDC cultures alone or added with the scrambled peptide GL37
(Figure 2.8.A). PDCs when activated by self-RNA-LL37 complexes produced
high levels of IFN-α, but this activation was not accompanied by production of the
proinflammatory cytokines TNF-α or IL-6. There was no significant qualitative
difference between pDC activations induced by self-DNA and self-RNA thus
implicating both the species of self nucleic acids in this
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Figure 2.8

A

B

Figure 2.8. LL37 converts self-RNA into a trigger for pDCs to produce IFN-α. (A) IFN-α
produced by pDCs after stimulation with increasing concentrations of total human RNA
purified from U937 cells (self- RNA), either alone (closed circles) or premixed with LL37
(self-RNA–LL37; open circles) or the scrambled peptide GL37 (self-RNA+GL37; open
squares). (B) IFN-α produced by pDCs after stimulation with self-RNA or self-DNA (both at 5
µg/ml) alone or in complex with LL37 (self-RNA–LL37 and self-DNA–LL37). Each symbol
represents an independent experiment; horizontal bars represent the mean.
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Figure 2.9

Figure 2.9. Self-RNA-LL37 complexes fail to induce maturation of pDCs. Flow
cytometric analysis of stimulated pDCs for CD80 and CD86 surface expression. CpG-2006
(1 µM) was used as a control to induce pDC maturation. Data are representative of at least
three independent experiments.
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Figure 2.10
A
*
*

*

B
**

*

Figure 2.10. Self-RNA from different sources induce similar levels of IFN-α in pDCs.
(A) IFN-α produced by pDCs after stimulation with total RNA (5µg/ml) from U937
(myelomonocytic leukemia), HACAT (keratinocytes) and 293ME (melanoma) cells with or
without premixing with LL37 (50 µg/ml). Data are presented as mean + s.e.m. of 3
independent experiments. (B) IFN-α produced by pDCs after stimulation with total RNA
(5µg/ml) isolated from healthy skin (n=4), plaque psoriasis (n=5), or atopic dermatitis (n=3)
with or without premixing with LL37 (50µg/ml). Mean + s.e.m of a representative experiment
is given. Experiments in (A) and (B) were also performed by pretreatment of purified RNA
with RNase A (50µg/ml) to ensure that responses were RNA-mediated. *p value <0.05,
paired Student’s T test.
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response. Also the pDCs failed to undergo maturation as assessed by surface
expression of the costimulatory molecules CD80 and CD86 (Figure 2.9).
To investigate whether the source of the total human RNA had something to do
with this activation event we used self-RNA isolated from a variety of cell types
and biopsies from various types of skin pathologies to do the stimulation of the
pDCs and we found RNA from all these sources induced similar levels of IFN-α
when in complex with LL37. This indicated that different cellular sources or
disease-dependent variations in total RNA composition do not have any
differential role to play in this activity (Figure 2.10.A&B). These experiments
proved that LL37 when interact with self-RNA can convert otherwise nonstimulatory self-RNA into a trigger for activation of the plasmacytoid dendritic
cells leading to production of IFN-α. Thus self-RNA released during host cell
death is able to induce innate immune activation.

Self-RNA-LL37

complexes

are

internalized

into

the

endosomal

compartments of pDCs.
A potent interferon production response of the pDCs to the self-RNA-LL37
complexes indicated that the pDCs are able to take up the particulate complexes
intracellularly. Indeed using Alexa 488 fluorophore labeled self-RNA (selfRNAAlexa488) in the RNA-peptide complexes after incubating the complexes with
the pDCs for 4 h 10-15% cells were found to be positive for Alexa 488
fluorescence on flow cytometry, indicating uptake of the fluorescently labeled
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Figure 2.11

Figure 2.11. LL37 transports self-RNA intracellularly into pDCs. (A) pDCs were
stimulated for 4 h with self-RNAAlexa488 alone or self- RNAAlexa488–LL37 and analyzed by
flow cytometry for self-RNAAlexa488-containing pDCs. (B) Confocal microscopy of pDCs
stimulated for 4 h with self-RNAAlexa488–LL37 complexes and stained with Alexa 647–labeled
anti–HLA-DR antibody to visualize the contour of the cell.
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complexes by the pDCs. When given alone self-RNAAlexa488 could not get
internalized (Figure 2.11.A) showing importance of the complex formation in this
internalization process. To confirm the localization of the self-RNA-LL37
complexes inside the cell we performed confocal microscopy using the labeled
complexes incubated with the pDCs for 4 h and then staining the pDCs with antiHLA-DR antibodies to delineate the cell boundary. On acquiring the images on a
confocal microscope the complexes were again found to be located inside the
cells (Figure 2.11.B).
Previous study on DNA-LL37 complexes done in our lab reported retention of the
DNA complexes in the early endosomes of pDCs (Lande R et al, 2007). To check
for the endosomal localization of the self-RNA-LL37 complexes in the pDCs the
cells after incubation with the labeled complexes for 4 h, were stained with either
the early endosomal marker Transferrin receptor or the late endosomal marker
LAMP-1. On confocal microscopy of these cells we found a lot more labeled
complexes to co-localize with the Transferrin receptor containing early
endosomes compared to the LAMP-1-positive late endosomes (Figure 2.12).
Thus the RNA-LL37 complexes after getting internalized into the pDCs were
retained in the early endosomal compartments for a long period of time and
possibly triggered the cognate receptors at this compartment. This phenomenon
could

explain

the

absence

of

costimulatory

molecule

expression

and

proinflammatory cytokine production in the pDCs in addition to induction of IFN-α
in line with previous reports, which showed early endosomal retention of TLRligands in pDCs lead to more robust type I IFN induction in the absence of
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Figure 2.12

Figure 2.12. Self-RNA-LL37 complexes are retained in early endosomes in pDCs.
pDCs were stimulated for 4 h with self-RNAAlexa488–LL37 (green) and then stained for HLADR (blue) along with either Transferring receptor or Lamp-1 (red). Confocal microscopy of
the stained pDCs were counted for relative abundance of complexes co-localizing with
either the Transferring receptor or LAMP-1 were assessed by counting 50 cells in multiple
fields. *p value <0.05, Student’s T test.
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maturation of pDCs and proinflammatory cytokine production (Honda K et al,
2005). On the contrary a late endosomal localization of the TLR-ligands leads to
an opposite response showing pDC maturation and proinflammatory cytokine
production while having less type I IFN induction (Honda K et al, 2005).

Activation of endosomal TLR7 in pDCs by the self-RNA-LL37 complexes.
To investigate whether the self-RNA-LL37 complexes, after being internalized by
pDCs and being located in the endosomal compartments, are able to trigger
endosomal TLR activation and whether this TLR activation is the mechanism of
induction of IFN-α by the pDCs, we used an inhibitor for vesicular H+K+-ATPase
Bafilomycin A1. Acidic pH is crucial for the toll-like receptor triggering in the
endosomes (Rutz M et al, 2004) and the vesicular proton pumps bring about this
acidification. Thus inhibiting the proton pumps leads to inhibition of TLR
triggering in the endosomes. When pDCs were stimulated with self-RNA-LL37
complexes in the presence of Bafilomycin, the IFN-α induction was inhibited in a
dose dependent-manner by this proton pump inhibitor, which blocks endosomal
acidification and TLR signaling (Figure 2.13.A).
PDCs have endosomal toll-like receptors for recognizing both DNA (TLR9) and
RNA (TLR7). The endosomal localization of the self-RNA-LL37 complexes and
the dependence of the activation response on endosomal acidic pH pointed to
possible involvement of TLR7 in the recognition of this complexed self-RNA. To
confirm this possibility we used a specific oligonucleotide inhibitor for TLR7
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Figure 2.13

A

B

*

*

C

Figure 2.13. Self-RNA-LL37 complexes trigger endosomal TLR7 activation in pDCs.
(A) IFN-α produced by pDCs stimulated with self-RNA–LL37 complexes after pretreatment
with increasing concentrations of bafilomycin. (B) IFN-α produced by pDCs after stimulation
with self-RNA–LL37, CpG-2006 (1 µM), or R837 (10 µg/ml) after pretreatment with 1 µM
TLR7 inhibitor C661 or a control oligonucleotide (ctrl-ODN). Data in A–D are representative
of at least three independent experiments; error bars in C and D represent the SD of
triplicate wells. (C) IFN-α produced by pDCs after stimulation with short single-stranded
RNA sequences ssRNA40 and ssPolyU alone (both 5µg/ml) or in complex with LL37.
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named C661 (Barrat FJ et al, 2005). There was inhibition of IFN-α induction by
the synthetic TLR7 agonist R837 but not the TLR9 agonist CpG2006 in presence
of when pDCs were pre-treated with C661 (Figure 2.13.B).

Also the

pretreatment of pDC with C661 prior to stimulation with the self-RNA-LL37
complexes abolished the IFN-α induction (Figure 2.13.B). This experiment
confirmed the involvement of TLR7 triggering by the self-RNA-LL37 complexes in
the activation of pDCs by these complexes.
To further support these data, we investigated whether the short synthetic singlestranded RNA sequences that can activate TLR7 in pDC upon liposomal
transfection (Diebold SS et al, 2004; Heil, F et al, 2004) were also internalized in
presence of LL37 and were able to trigger IFN-α induction. These short
sequence RNA molecules also formed particulate complexes with LL37 (data not
shown) and these complexes were able to induce IFN-α production by pDCs
(Figure 2.13.C).

Self-RNA-LL37 complexes activate myeloid DCs leading to their maturation
and production of proinflammatory cytokines.
Ability of the self-RNA-LL37 complexes to access the endosomal compartments
in the plasmacytoid dendritic cells opened up the possibility of activation of
myeloid dendritic cells by these nucleic acid-endogenous peptide complexes and
thus leading to broader autoimmune activation. Although DNA-LL37 complexes
also are able to access pDC endosomes and trigger TLR9 to induce type I IFN
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production in pDCs, they failed to show any activating response on mDCs. That
could be explained by the absence of TLR9 or any other DNA-responsive
receptor in the endosomal compartments of human mDCs (discussed in Section
1.3 & 1.4). But mDCs in human do express multiple toll-like receptors in the
endosomal compartments that recognize RNA (Kadowaki N et al, 2001;
Jarrossay D et al, 2001; Hornung V et al, 2002). TLR3 and TLR8, expressed in
mDC

endosomes,

recognize

double-stranded

and

single-stranded

RNA

molecules respectively.
To investigate whether mDCs can respond to self-RNA when complexed with
LL37 leading to their activation, we stimulated immature monocyte-derived mDCs
or mDCs isolated directly from human peripheral blood with self-RNA alone or in
complex with LL37. Self-RNA, when in complex with LL37 but not when given
alone, induced activation of mDCs. The mDCs thus stimulated produced
proinflammatory cytokines TNF-α and IL-6 (Figure 2.14 and 2.16.B). The mDCs
were not able to produce any IFN-α unlike the pDCs stimulated in the same
manner. Self-RNA-LL37 complexes also led to maturation of the mDCs as
evident by upregulation of the B7 costimulatory molecules CD80 and CD86
expression on the cell surface (Figure 2.15.A&B). This activation of mDCs in
response to self-RNA-LL37 complexes was entirely dependent on presence of
self-RNA I the complex, found by abrogation of these responses by decreasing
the amount of self-RNA in the complexes (data not shown). As expected selfDNA-LL37 complexes, as opposed to self-RNA-LL37 complexes, were not able
to bring about similar activation of the mDCs (Figure 2.14 and Figure 2.15).
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Figure 2.14

Figure 2.14. Self-RNA but not self-DNA in complex with LL37 activates monocytederived mDCs to secrete TNF-α and IL-6. Immature monocyte-derived mDCs were
stimulated with self-RNA, self-DNA, self-RNA–LL37, or self-DNA–LL37. TNF-α and IL-6
secretion was measured after overnight culture. Each symbol represents an independent
experiment, and horizontal bars represent the mean.
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Figure 2.15
A

B

Figure 2.15. Self-RNA-LL37 complexes induce maturation in monocyte-derived mDCs.
(A) Flow cytometry for surface expression of CD86 and CD80 on stimulated mDCs. LPS
was used as a control to induce mDC maturation. (B) Mean fluorescence intensity (MFI)
changes for CD86 and CD80 expression on mDCs in response to stimulation with selfRNA–LL37 complexes. Each symbol represents an independent experiment, and horizontal
bars represent the mean. *, P < 0.0005; paired Student’s T test.
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Figure 2.16
A

B

Figure 2.16. Self-RNA-LL37 complexes induce proinflammatory cytokine production
and maturation in circulating CD1c+ mDCs. (A) Flow cytometry for surface expression of
CD86 and CD80 on stimulated CD1c+ mDCs isolated from peripheral blood. (B) TNF-α and
IL-6 production by circulating CD1c+ mDCs stimulated with self-RNA either alone or mixed
with LL37. Data are presented as mean + s.e.m. of 3 independent experiments.
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These phenomenon of the ribonucleic acids of self origin being able to access
the endosomal compartments of the mDCs when in complex with the
endogenous peptide LL37 leading to activation and maturation again pointed to
the possibility of innate immune activation of the mDCs in response to nucleic
acids released during host cell death. These experiments were done with pure
RNA molecules isolated from human cells and so it remained to be seen whether
RNA derived from a more physiological source like the same released by dying
human cells were also able to show similar activity. Toward this we used
supernatants of UV-irradiated human cells as done with pDCs before (described
in Section 2.1.a). As described before UV-irradiation of the cells followed by
overnight incubation leads to apoptosis of the cells followed by secondary
necrosis and as a result nucleic acids are released into the supernatant.
Stimulation of the myeloid DCs with these supernatants added with LL37 also
induced activation of the mDCs as evident by the production of the
proinflammatory cytokine TNF-α (Figure 2.17). In case of mDCs, as opposed to
pDCs, this activity was completely abolished when self-RNA was depleted from
those supernatants by pre-treating the supernatants with RNase before adding
LL37 showing that this activity was entirely dependent on the self-RNA released
during cell death (Figure 2.17). DNA present in the supernatants was not taking
part in this activation as shown by lack of abolition of activity on pre-treatment of
the supernatants with DNase (Figure 2.17). This was in line with our finding that
self-DNA-LL37 complexes were unable to induce mDC activation.
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Figure 2.17

Figure 2.17. RNA, but not DNA, released during cell death can activate mDCs in
presence of LL37. TNF-α production by mDCs stimulated with supernatants of dying U937
cells, either alone or premixed with LL37. In some experiments, DNA and/or RNA was
depleted from supernatants of dying cells by pretreatment with DNase I and/or RNase A.
Data indicate the mean ± SEM of three independent experiments. *p value <0.05, paired
Student’s T test.
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Self-RNA-LL37 complexes trigger TLR8 activation in the endosomal
compartment in mDCs.
To investigate the mechanism of this activation of the myeloid DCs in response
to the self-RNA-LL37 complexes we wanted to confirm access of these
complexes to the endosomal compartments of the mDCs and TLR triggering
therein. Self-RNAAlexa488 was added to mDC cultures alone or in complex with
LL37 to look for uptake of the complexes by the mDCs. On doing both flow
cytometry and confocal microscopy, we found the labeled RNA to be internalized
into the mDCs when in complex with LL37 but not when given alone after 4h
(Figure 2.18). To investigate the endosomal localization of the self-RNA-LL37
complexes inside the mDCs the cells were also stained with early and late
endosomal markers (Transferrin receptor and LAMP-1 respectively) and the
complexes were seen co-localizing with these markers, thus confirming their
endosomal location. But, in contrary to pDCs, there was no relative retention of
these complexes in the early endosomes.
The production of the proinflammatory cytokines TNF-α and IL-6 by the mDCs in
response to the self-RNA-LL37 complexes but not by TLR4 agonist LPS was
found to be completely abrogated when Bafilomycin was added to the cultures to
block the vesicular proton pumps in the DCs to reverse the acidic pH conducive
for endosomal TLR triggering (Figure 2.19A). This demonstrated that this
activation of the mDC by self-RNA-LL37 complexes involved activation of the
TLRs in the endosomes.
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Figure 2.18

A

B

Figure 2.18. LL37 transports self-RNA into mDCs. (A) mDCs were stimulated for 4 h with
self-RNAAlexa488 alone or self-RNAAlexa488–LL37 and analyzed by flow cytometry for selfRNAAlexa488–containing mDCs. (B) Confocal microscopy of mDCs stimulated for 4 h with
self-RNAAlexa488–LL37 complexes and stained with Alexa 647–labeled anti–HLA-DR antibody
to visualize the contour of the cell. Data in A and B are representative of at least five
independent experiments.
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MDCs express multiple endosomal TLRs (TLR3 and TLR8) that can recognize
RNA. Total human RNA consists of RNA molecules that can potentially be
recognized by both TLR3 and TLR8, recognizing respectively double-stranded
and single-stranded RNA molecules. To investigate whether both of these TLRs
are involved in sensing self-RNA-LL37 complexes or one of them is responsible
for this recognition, we performed gain-of-function reporter assay using 293T
cells. In this experiments using 293T cells transfected with either TLR8 or TLR3
expression vectors along with an NFκB-luciferase reporter plasmid, it was
revealed that self-RNA-LL37 complexes could induce NFkB activation only in the
TLR8-transfected 293T cells, but not in the TLR-expressing cells. Thus we found
that these RNA-peptide complexes were sensed by TLR8 but not by TLR3
(Figure 2.19.B). Bringing further support to this finding, we used the synthetic
short RNA sequences that activate TLR8 in human mDCs (Diebold SS et al,
2004; Heil, F et al, 2004), added them in mDC cultures alone or in complex with
LL37 and found that they could also activate the mDCs when complexed with
LL37 but not when given alone (Figure 2.19.C).

PDC-derived IFN-α enhances self-RNA-LL37 induced maturation of mDCs.
Type I IFNs have been shown to directly induce myeloid DC activation and
maturation (Luft T et al, 1998; Santini SM et al, 2000) and plasmacytoid DCs are
the most potent producers of type I IFN in the body. Thus through type I IFNs
pDCs and mDCs can cooperate and synergize during an immune response. In
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Figure 2.19
A

B

C

Figure 2.19. Self-RNA-LL37 complexes trigger endosomal TLR8 activation in mDCs.
(A) TNF-α and IL-6 secretion by mDCs stimulated with self-RNA–LL37 complexes after
pretreatment with increasing concentrations of bafilomycin. Stimulation of the mDCs with
LPS was used as negative control. Data are representative of three independent
experiments. (B) NF-κB promoter activity of TLR8- or TLR3-transfected HEK293 cells
measured by luciferase reporter assay after stimulation at the indicated conditions. Data in
D are the mean ± SEM of five independent experiments. *, P < 0.05; paired Student’s T test.
(C) TNF-α (black) and IL-6 (white) secretion by mDCs after stimulation with short singlestranded RNA sequences ssRNA40 and ssPolyU alone or in complex with LL37.
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our studies we found that both these subsets of human dendritic cells are able to
sense self nucleic acids, in the context of the endogenous antimicrobial peptide
LL37, through triggering of the endosomal TLRs. While pDCs can respond to
both DNA and RNA, mDCs are able to respond only to RNA in this context. But
the type I IFN produced by pDCs in response to the self nucleic acid-AMP
complexes is potentially able to affect also the mDCs. As the responsible AMP is
expressed in a clinical context involving host cell death associated with
extracellular release of both DNA and RNA molecules and both pDCs and mDCs
have been shown to be recruited in such inflammatory processes, there is
possibility of a cooperative synergy between these two DC subsets mediated
through type I IFNs.
To investigate this possibility we wanted to see whether supernatants, derived
from the pDC cultures stimulated with self-DNA-LL37 complexes, when added in
mDC cultures before being stimulated with the self-RNA-LL37 complexes, could
enhance the activation and maturation response. When we compared the effects
of stimulation with either the supernatant of activated pDCs or self-RNA-LL37
alone on mDCs with the response in presence of a combination of both, we
found significant enhancement of production IL-6 and TNF-α by the mDCs
(Figure 2.20.A) and their differentiation into mature CD83+ DCs by the combined
stimulation (Figure 2.20.B). When we added an antibody cocktail containing
neutralizing antibodies against IFN-α, IFN-β and the IFN-αβ receptor in the
supernatant from the activated pDC culture this cooperative enhancement
response in mDCs was completely blocked (Figure 2.20.B). This demonstrated
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Figure 2.20

Figure 2.20. IFN-α induced by concomitant pDC activation enhances maturation and
cytokine production by mDCs. (A) Flow cytometry for CD86, CD80, and CD83 surface
expression. Data are representative of at least three experiments. (B) TNF-α and IL-6
secretion measured by ELISA. Each symbol represents an independent experiment, and
horizontal bars represent the mean. *p value <0.05, paired Student’s T test.
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that the enhancement of mDC activation, in presence of the supernatant from
activated pDC culture, was mediated by the type I IFNs present in that
supernatant. Thus, the activation and maturation of mDCs in response to the
self-RNA-LL37 complexes can be enhanced by the concomitant activation of
pDCs to produce IFN-α.
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2.3. Chapter 3: Pathologic relevance of immune recognition of
self nucleic acids in the context of autoimmune diseases
In the studies done in our lab we found that the endogenous cationic
antimicrobial peptide LL37 can go into an electrostatic interaction with anionic
nucleic acid molecules of self origin and transport them into the endosomal
compartments of both pDCs and mDCs to induce TLR activation (Lande R et al,
2007; Ganguly D et al, 2009). These findings identify a novel pathway for
autoimmune activation to self nucleic acids in human diseases. To confirm the
relevance of these biological phenomena in clinical settings we wanted to look at
human autoimmune diseases where this pathway can play a key role
hypothetically.

First of them is naturally Psoriasis, as LL37 is over-expressed in psoriatic
epidermis and it was identified to be the active principle present in psoriatic skin
extract that was shown to trigger pDC activation and type I IFN induction (Lander
R et al, 2007) and this pDC-derived type I IFNs have been shown to be
instrumental for disease initiation (Nestle FO et al, 2005). Ability of LL37 to
interact with self-RNA opened the possibility of TLR activation concomitantly in
pDCs and mDCs through the same pathway that leads to self-DNA-mediated
pDC activation and thus could explain the presence of activated mDC in the
psoriatic skin as reported earlier (Lowes MA et al, 2005).

Another autoimmune condition, where this autoimmune activation to self nucleic
acids can play a key role, is systemic lupus erythematosus or SLE. In SLE
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autoreactive B cells producing autoantibodies against self-DNA, chromatin, and
RNA-associated proteins are circulating in blood and insoluble immune
complexes formed by these circulating autoantibodies with extracellular selfnucleic acids get deposited in different tissues resulting in local inflammation and
tissue injury. Moreover, type I IFNs and pDCs have been reported to play an
important role in SLE pathogenesis (Theofilopoulos AN et al, 2005; Blomberg S
et al, 2001).

2.3.A. Psoriasis
2.3.A.a. Background and Rationale
As depicted above psoriatic skin lesions show a very high level of expression of
the cationic antimicrobial peptide LL37 and we found that LL37 can interact with
both DNA and RNA molecules of self-origin to make particulate complexes that
are then internalized into both the plasmacytoid and myeloid dendritic cells. This
enables the self nucleic acids to access the endosomal toll-like receptors and
trigger innate immune activation. On the other hand local tissue injury has been
shown to trigger aggravation of psoriatic disease progression, termed as
Koebner’s phenomenon (discussed in Section 1.6). To link these findings and to
establish our hypothesis of innate immune activation in Psoriasis in response to
Nucleic acid-AMP complexes, we wanted to look for the particulate complexes
formed by self-nucleic acid and the AMP molecules in situ taking cryosections
from involved skin of psoriatic patients. Also we wanted to investigate whether
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the activation of infiltrating mDCs in the lesions can be linked to the presence of
the ribonucleic acid particles being formed in situ.

2.3.A.b. Materials and Methods
Collection of human samples.
The study with clinical samples from patients was approved by the Institutional
Review Board for human research at the M. D. Anderson Cancer Center in
Houston and the Heinrich-Heine University in Düsseldorf. Skin samples were
collected by 6-mm punch biopsies from normal skin of healthy subject, from
lesional skin of patients with chronic plaque psoriasis and atopic dermatitis. The
clinical

conditions

were

defined

according

to

standard

clinical

and

histopathological criteria. Cryosections were prepared from these biopsy
specimens.

Immunofluorescence and immunohistochemistry.
Immunofluorescence staining for nucleic acids was done on cryosections with the
nucleic acid dyes DAPI (Sigma-Aldrich, MO) and Ribogreen (Molecular Probes,
CA). The cryosections after thawing were fixed in acetone for 10 min at 4oC.
Acetone-fixed sections were then washed in PBS and incubated with the
blocking buffer (PBS with 2% goat serum, 0.1% fish gelatin and 0.05% Tween20)
for 30 min at room temperature. Then the sections were incubated with mouse
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anti-LL37 (mAb 3d11, Hycult Technologies) or anti-DC-LAMP antibody (mAb
104.G4, Coulter Immunotech) or isotype control overnight, followed by further
washes and incubation with Alexa 647-conjugated anti-mouse IgG secondary
antibody for 30 min at room temperature. After washes the sections were
incubated with DAPI (0.1ng/ml) and Ribogreen (1:100000) for 5 min to stain the
nucleic acids. Then the slides were washed, mounted with prolong gold mounting
medium (Molecular Probes, CA) and stored at 4oC till the images were acquired.
Ribogreen and DAPI were added following the antibody incubations for best
staining efficiency. The images were acquired in a Leica TCS SP2 confocal
microscope and analyzed with Leica confocal software.
Immunohistochemical staining for DC-LAMP on these cryosections from psoriatic
skin biopsies were done using mouse anti-DC-LAMP antibody (mAb 104.G4,
Coulter Immunotech, Marseille, France). Peroxidase-conjugated secondary
antibody was used with DAB detector reagent. Images were acquired with an
Olympus DP70 microscope.
The extracellular RNA complexes and the DC-LAMP+ DCs in the tissue sections
were quantitated by two independent investigators who counted three best fields
in each section.

Statistical analysis.
Comparison between samples from different clinical conditions for the number of
extracellular RNA particles was statistically validated by unpaired Students’ T
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test. Correlation studies were analyzed by two-tailed Pearson’s correlation (p <
0.05 was considered statistically significant). Statistical evaluations were done on
GraphPad Prism software (La Jolla, CA).

2.3.A.c. Results & Discussion:
Nucleic acid complexes are present in psoriatic skin.
Our lab has previously demonstrated that the antimicrobial peptide LL37 is highly
expressed in the epidermis of the inflamed skin in psoriatic patients, while they
are undetectable in the skin affected with atopic dermatitis or healthy skin (Lande
R et al, 2007). The in vitro studies, revealing the ability of the LL37 peptide to
interact with self-origin DNA and RNA molecules and form particulate complexes,
led to the possibility of these complexes to be formed also in vivo. Moreover, as
these nucleic acid-peptide particulate complexes were microscopically visible we
set on to find these complexes in situ in the cutaneous cryosections from
psoriatic patients.
The initial goal was to find extracellular nucleic acids in the tissue sections and
for these we stained the cryosections with two nucleic acid dyes DAPI and
Ribogreen to differentiate between DNA and RNA complexes. DAPI binds
preferentially to DNA, while Ribogreen binds both DNA and RNA and is very
sensitive to even low amounts of RNA (Jones LJ et al, 1998). Thus we defined
extracellular RNA complexes to be extracellular particulate structures stained
only with Ribogreen but not with DAPI, and DNA complexes as similar structures

Figure 2.21. Extracellular RNA complexes are present in psoriatic skin. (A) Confocal microscopy
image of a representative psoriatic skin lesion stained with DAPI (red) and Ribogreen (green). DNA in
cell nuclei appears yellow (Ribogreen+/DAPI+), and arrowheads indicate extracellular RNA aggregates
appearing green (Ribogreen+/DAPI-). Bar, 50 µm. (B) Numbers of visible extracellular RNA aggregates in
the dermal compartment of healthy skin (n = 9), psoriatic skin (n = 11), and atopic dermatitis (n = 10). **,
P = 0.0295; *, P = 0.042; unpaired Student’s T test (both two-tailed). (C–F) High magnification images of
extracellular RNA aggregates in the dermal compartment of psoriatic skin lesions. Bar, 10 µm. (E and F)
SFP projection of panel D.

Figure 2.21
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doubly stained by the both dyes. Under a laser-scanning confocal microscope we
could find a lot of extracellular Ribogreen+DAPI- complexes in the dermal
compartment of psoriatic skin lesions (Figure 2.21.A).
We also looked for similar complexes in cryosections from the skin affected with
atopic dermatitis or in skin samples from healthy donors and the abundance of
such particulate RNA complexes were significantly low in these cryosections
(Figure 2.21.B). This was compatible with our hypothesis as healthy skin as well
as skin affected with atopic dermatitis do not express the cationic antimicrobial
peptides in contrast to their high expression in psoriatic skin. The self-RNA-LL37
complexes showed a characteristic branched and aggregated beads structure as
found in vitro (Figure 2.21.C-F). As expected a lot of Ribogreen+DAPI+ DNA
complexes were also found in the psoriatic skin sections.

Nucleic acid complexes in psoriatic skin contain LL37.
The extracellular RNA complexes in situ shared several morphological features
with the RNA-LL37 complexes generated in vitro. The similarities in the size of
the particles, the characteristic morphology of branched aggregates of bead-like
structures resulting from the aggregation of smaller particles and the very fact of
their sustenance in frozen tissue perhaps due to relative resistance to
extracellular enzymatic degradation raised the possibility of similar interaction
between cationic peptides and nucleic acids to be behind their formation as we
found in vitro.
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Figure 2.22
A RNA complexes in vitro

B RNA complexes in situ

C DNA complexes in situ

Figure 2.22. Extracellular RNA complexes in psoriatic skin show presence of LL37.
(A) Representative confocal microscopy images of in vitro–generated self-RNA–LL37
complexes stained with Ribogreen (green) and an anti-LL37 antibody (red). (B)
Representative confocal microscopy images of RNA–LL37 aggregates in psoriatic skin
cryosection stained with Ribogreen (green) and an anti-LL37 antibody (red). Extreme right:
SFP projection of middle panel. (C) Representative confocal microscopy images of DNA–
LL37 complexes in psoriatic skin stained with DAPI (blue), Ribogreen (green) and anti-LL37
antibody (red) Bars, (A) 10 µm; (B) 2 µm.
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To confirm this speculation we investigated whether the extracellular RNA
complexes found in the tissues showed concomitant presence of LL37. First we
wanted to establish the detection of this peptide on the in vitro formed RNA
particles with an antibody. We could stain LL37 on the in vitro generated
complexes by staining the self-RNA-LL37 particles with anti-LL37 and Ribogreen
(Figure 2.22.A). Interestingly, we found that the antibody was not bound all over
perhaps due to a mutual exclusion of sites for antibody binding to the complex
and Ribogreen staining. By doing similar staining on the cryosections from
psoriatic skin biopsies for the complexes with an anti-LL37 antibody we found
that on a lot of these extracellular RNA complexes presence of LL37 could be
detected (Figure 2.22.B), similar to the RNA-LL37 complexes in vitro. A lot of the
extracellular DNA complexes, identified as Ribogreen+DAPI+ structures, were
also found to show similar presence of LL37 on them (Figure 2.22.C).

Abundance of self-RNA complexes in psoriatic skin can be linked to mDC
activation.
Finding the RNA-LL37 complexes in situ in the lesional skin of psoriatic patients
led to further investigations to look for whether the presence of these RNAcomplexes is linked to the activation of mDCs that infiltrate the psoriatic skin
lesions. We looked in serial sections of lesional kin for the activated mDCs by
immunohistochemical staining of the sections for the expression of DC-LAMP, a
lysosomal marker that is specifically expressed in activated and mature mDCs.
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Figure 2.23

A

B

Figure 2.23. Extracellular RNA complexes in psoriatic skin is associated with mDC
activation in situ. (A) Immunohistochemical results for DC-LAMP in a representative
psoriatic skin lesion. Bar, 50 µm. (B) Correlation between the numbers of DC-LAMP+ mDCs
and the numbers of visible extracellular RNA aggregates in multiple psoriatic skin lesions (n
= 11). Pearson R = 0.615, two-tailed p = 0.044. SFP, simulated fluorescence Projection.
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We found clusters of DC-LAMP positive mature mDCs at the epidermal-dermal
junctions and in the dermis of the lesional skin (Figure 2.23.A), which was
consistent with earlier reports (Lowes MA et al, 2005).
To investigate whether relative abundance of the RNA-complexes in the lesions
could be linked to the frequency of activated mDCs found in the same lesions we
compared lesional tissue sections from 11 psoriatic patients. We found a very
significant correlation between the numbers of RNA-complexes found with the
number of activated mDCs seen (Figure 2.23.B). This quantitative correlation
pointed to a mechanistic link between the in situ RNA-complexes and mDC
activation.

Self-RNA complexes can be seen associated with endolysosomal
compartments in mDCs
In our experiments where we stained cryosections from lesional skin from
psoriatic patients we found numerous RNA-complexes near or within the clusters
of activated mDCs. The activation of mDC in these was indicated by the
expression of DC-LAMP. DC-LAMP is a membrane-bound glycoprotein
expressed in the endolysosomal compartments of myeloid dendritic cells induced
upon maturation of the DCs (de Saint-Vis B et al, 1998). We found (described in
Section 2.2) that the RNA-LL37 complexes are taken up into the endosomal
compartments in mDCs where they trigger TLR8 activation. In some of the
stained cryosections of lesional skin from psoriatic patients we could even find
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Figure 2.24

DAPI/Ribogreen/DC‐LAMP

Figure 2.24. Extracellular RNA complexes can be found within endolysosomal
network of activated mDCs in situ. Confocal microscopy images of DC-LAMP+ mature
mDCs (red) in the dermal compartment of a representative psoriatic skin lesion co-stained
with DAPI (blue) and Ribogreen (green). The images depict DC-LAMP (top left), DAPI (top
right), and the merged image of DAPI and Ribogreen (bottom left). The merged image
(bottom right) shows the colocalization of RNA complexes (Ribogreen+/DAPI-; green) with
DC-LAMP–positive organelles (red) appearing yellow. Bar, 10 µm.
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RNA-complexes inside the endo-lysosomes of mDCs. The Ribogreen+DAPIcomplexes were found to co-localize with DC-LAMP positive vesicles on costained sections (Figure 2.24).
Taken together our findings strongly supported the hypothesis that extracellular
RNA complexes present in lesional skin can drive mDC activation in vivo. Also
these studies confirmed involvement of this antimicrobial peptide-driven immune
recognition of self nucleic acids leading to innate immune activation in this
cutaneous autoimmune disease.

2.3.B. Systemic lupus erythematosus
2.3.B.a. Background and Rationale
We have found in our studies with tissue samples from lesional skin of psoriatic
patients that the antimicrobial peptide-driven innate immune recognition of self
nucleic acid plays a major role in the initiation of the inflammatory cascade in this
cutaneous autoimmune disease. On the other hand other studies done in the lab
interestingly found that the antimicrobial peptide LL37 is present in the immune
complexes isolated from the serum of patients affected with systemic lupus
erythematosus or SLE (Lande R a et al, 2010). Moreover these immune
complexes could activate pDCs to induce type I IFN production and this activity
could be abolished when the immune complexes were depleted of the
antimicrobial peptides (Lande R et al, 2010). These findings, along with the
established knowledge of autoimmunity to self nucleic acids and nucleoproteins
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and circulating autoantibodies to these molecules in SLE, intrigued us to
investigate whether this presence of antimicrobial peptides in the SLE immune
complexes is also due to the electrostatic interaction with the self nucleic acid
molecules and whether they bear the characteristic morphology as seen with
nucleic acid-AMP complexes in vitro and in psoriatic lesions (Ganguly D et al,
2009). This was interesting as it may be that the existence of these complexes in
the circulating blood and in different tissue spaces is due to the relative
resistance of the complexes to extracellular enzymatic degradation conferred by
the interaction with antimicrobial peptides. It was also interesting to explore the
potential source of the nucleic acids in the SLE immune complexes.

2.3.B.b. Materials and Methods
Reagents.
Synthetic LL37 peptide (LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES)
was from Innovagen (Lund, Sweden). Natural human neutrophil peptides [HNP(13)]

were from Hycult Biotechnology (Canton, MA). Human genomic DNA (3 µg/ml)

was procured from BioChain (Hayward, CA). DNase I (200 U/ml) was from
Roche (Nutley, NJ). Monoclonal antibody against LL37 (clone 8A8, IgG2b, OK)
was generated by immunizing 6- to 8-wk-old BALB/c mice with synthetic LL37
peptide and was used at 10 µg/ml. Monoclonal antibody against HNPs (clone
3G9, IgG2a) was from Novus Biological (Littleton, CO) and was used at 10 µg
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ml–1. Monoclonal antibody against dsDNA (clone H241, IgG2b, OK) was a kind
gift from Dr. Stollar, Tufts University, and was used at 10 µg/ml.

Collection of human samples.
Studies with human samples were approved by the Institutional Review Board for
human research at The University of Texas M. D. Anderson Cancer Center in
Houston and the Kansai Medical University in Osaka. The diagnosis of SLE was
based on the American College of Rheumatism criteria for SLE. For purification
of immune complexes, only sera from SLE patients with anti-DNA titers >60 IU/ml
were selected (provided by The Binding Site Inc., San Diego, CA). Total IgGs
from the sera of SLE patients and healthy controls were isolated with use of a
HiTran TM Protein-G HPLC (GE Healthcare, Piscataway, NJ). Immune
complexes (SLE-IC) were separated from monomeric IgGs by using an Amicon
centrifugal filter device with a 300,000 nominal molecular weight limit cutoff.

Microscopic visualization of immune complexes.
Total human genomic DNA (self-DNA) was purchased from BioChain (Hayward,
CA) or extracted from U937 cells by using standard procedures. Artificial immune
complexes containing Self-DNA were generated by adding self-DNA (3 µg/ml)
with LL37 (10 µM), HNP(1-3) (10 µM), and anti-dsDNA antibodies (1 µg/ml) in 20 µl
of phosphate-buffered saline (PBS) and incubated for 30 min at room
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temperature. For visualization of the complexes, suspensions containing in vitro–
generated artificial immune complexes or purified SLE immune complexes were
spun down and stained with DAPI (0.1 ng/ml, Sigma-Aldrich) and analyzed by
confocal microscopy. In some experiments, the artificial immune complexes and
the purified SLE immune complexes, in a volume of 20ul, were treated for 1 h
with DNase I (Roche, 600 U/ml) or the anionic polypeptide poly aspartic acids
(5,000-15,000 molecular weight), from Sigma-Aldrich and used at 10 µM, to
provide an excess of negative charge.

Nuclease protection assay.
To investigate the susceptibility of different DNA complexes self-DNA alone,
DNA-LL37 complex, DNA added with anti-DNA antibody and DNA-LL37 added
with anti-DNA antibody were run on a 1% agarose gel. The same samples were
also treated with DNase 200U/ml before running on the gel to look for sensitivity
of the samples to DNase degradation.

Induction of NETosis in neutrophils.
For isolation of human neutrophils from the circulating blood of healthy donors,
we first treated whole peripheral blood with a ACK lysing buffer (Lonza,
Walkersville, MD) to lyse erythrocytes and then isolated neutrophils by using antiCD15-conjugated microbeads (from Miltenyi Biotec). 93-94% of CD15+ cells were
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neutrophils that express high levels of CD15 (eosinophils and some monocytes
also express low levels of CD15). Purified neutrophils were seeded at 50 x 106
cells/ml in complete RPMI medium and either left untreated or stimulated with
PMA (Sigma-Aldrich, 20 ng/ml), anti-LL37 (10 µg/ml), anti-HNP (10 µg/ml), antidsDNA, or IgG control antibodies (10 µg/ml) in a 96 well plate followed by
transfer of the cells on poly-L-lysine coated coverslips and incubated for 3 h at
37oC.

Microscopic visualization of NETs.
For microscopic visualization and quantitation of NETosis, stimulated neutrophils
(as described above) were seeded on coverslips pretreated with poly-lysine.
Coverslips were washed gently after 3 hours, put on glass slide and visualized
under an immuno-fluorescence microscope (Olympus BX61). We did not use any
mounting medium to prevent loss of extracellular DNA fibrils. The quantitation
involved scoring of the NET density by two independent observers. The 1-10
scoring system was arbitrated taking less than 10% percent cover-up area of
extracellular DNA fibrils as score 0 and more than 90% of the same as score 10.

Statistical analysis
Statistical significance of differences was determined by Student’s t test and
ANOVA and Bonferroni’s t test (p < 0.05 was considered statistically significant).
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2.3.B.c. Results & Discussion:
SLE immune complexes consist of DNA micro-particles
As found in other studies done in our lab (Lande R et al, 2010), immune
complexes isolated from sera of SLE patients contain neutrophil-derived
endogenous antimicrobial peptides LL37 and alpha defensins (HNPs, Human
Neutrophil-derived peptides). In our previous studies we found (as described in
Section 2.1) that LL37 can bind to both human DNA and RNA and form
characteristic micro-particles that are visible under microscope. Lupus immune
complexes are conventionally thought to be composed of self nucleic acids,
nucleoproteins and antibodies to these self molecules. But the presence of the
cationic AMP LL37 in those complexes by Lande R et al led us to investigate
whether there is any interaction between the nucleic acid molecules and LL37
contained in the SLE immune complexes.
When the immune complex suspension (>300kD molecular weight) isolated from
Lupus sera was spun down we found a precipitate in the centrifugation tube. On
re-suspending the precipitate in PBS and staining with DAPI, the DNA-binding
dye, we found characteristic particulate aggregates with similar morphology as
the DNA-LL37 or RNA-LL37 particles described before (in Section 2.1) (Figure
2.25). To confirm this observation we made artificial immune complexes by
adding all the identified constituents in vitro like human DNA, anti-DNA antibody,
LL37 and HNP in indicated amounts. This also gave a precipitate on
centrifugation and on staining the precipitate with DAPI after re-suspension in
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Figure 2.25

Figure 2.25. SLE Immune complexes show the characteristic aggregated-particle
morphology of nucleic acid-AMP complexes. Confocal microscopy image of DNAcontaining immune complexes (IgGs >300 kDa) (left) and artificial immune complexes
(formed by DNA, LL37, HNP and anti-DNA antibody) detected as insoluble particles that
stained with DAPI. Bar = 10 µM.
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PBS we found similar particulate aggregates just as seen in immune complexes
from Lupus sera (Figure). These observations indicated that the nucleic acid
molecules and the cationic AMPs contained in Lupus immune complexes might
interact to form particulate complexes.

Immune complex micro-particles form by electrostatic interaction between
antimicrobial peptides and nucleic acids
When we found the characteristic micro-particles formed with the Lupus immune
complexes, it led us to speculate that a similar electrostatic interaction as we
found in vitro between self-DNA or self-RNA and LL37 is also operating in this
case (discussed in Section 2.1; Ganguly D et al, 2009). To prove that these
complexes are indeed formed by electrostatic interaction between the cationic
peptide and anionic nucleic acid molecules, we added poly-aspartic acid, an
anionic polymer, to competitively inhibit this interaction. These particulate
complexes dissolved rapidly when added with poly-aspartic acid pointing to an
electrostatic interaction in forming these complexes (Figure 2.26).
We have previously shown that the particulate complexes formed by DNA and
RNA with LL37 are protected from enzymatic degradation (discussed in Section
2.1; Ganguly D et al, 2009) due to condensation of the nucleic acids in presence
of the cationic peptides. We speculated that similar protection from enzyme
digestion could also play a role in sustenance of these nucleic acid containing
immune complexes. Both the complexes isolated from Lupus sera and the
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Figure 2.26

Figure 2.26. The artificial and natural Immune complexes form by electrostatic
interaction and are protected from enzymatic degradation. Number of DNA-LL37/HNP
+anti-DNA artificial complexes (left) and natural DNA/anti-DNA complexes (right) counted as
insoluble DAPI+ particles with or without treatment with DNase I or poly-ASP and in the
presence of increasing concentration of NaCl. Particles counted under a confocal
microscopy and represented as number in a confocal microscopic field with a 63.5X
objective.
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artificial immune complexes made in vitro were protected from DNase
degradation (Figure). To confirm that the antimicrobial peptides present in the
immune complexes are responsible for this protection of DNA and not the antiDNA antibodies present, we did one agarose gel electrophoresis based nuclease
protection assay with DNA alone, DNA-LL37 complex, DNA with anti-DNA
antibody and DNA-LL37 complex with anti-DNA antibody. We found that only in
presence of LL37 in the complexes the DNA contained in the complex is
protected from DNase activity, but not with anti-DNA antibody (Figure 2.27). This
indicated that the antimicrobial peptides contained in Lupus immune complexes
protect the nucleic acids in immune complex micro-particles from enzymatic
degradation and this protection cannot be achieved by the antibodies to nucleic
acids present in the immune complexes.

NETosis in neutrophils is a potential source of the immune complex microparticles
In our studies we found that nucleic acid-endogenous antimicrobial peptide
complexes, similar to what we found in case of the cutaneous autoimmune
disease Psoriasis, is present and they play an important role in immune complex
mediated systemic disease in Lupus. But a very important question was what is
the source of these complexes in SLE sera. A relevant knowledge derived by
previous reports in SLE pathogenesis is the presence of circulating apoptotic
neutrophils in SLE patients, abundance of which has been correlated with
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Figure 2.27

A: DNA alone
B: DNA‐LL37
C: DNA+anL‐DNA
D: DNA‐LL37+anL‐DNA

Figure 2.27. Protection of DNA from enzymatic degradation is mediated by the
presence of LL37 in the complexes. Agarose gel electrophoresis of human DNA alone
(A), human DNA in complex with LL37 (B), anti-DNA antibodies (C), or LL37 plus anti-DNA
antibodies (D) before and after treatment with DNase I. The DNA was visualized by ethidium
bromide staining.
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disease progression and autoantibody production (discussed in Section 1.7;
Courtney PA et al, 1999; McConnell JR et al, 2002). Apoptotic neutrophils can
potentially be a rich source of extracellular DNA in the sera. Moreover, very high
production of the AMPs in question, LL37 and HNP, by the neutrophils creates
the possibility of them being the source of the nucleic acid-AMP complexes we
found in the immune complexes. LL37 and HNP are known to be stored in the
secretory granules in neutrophils and they are released on degranulation (Lehrer
RI, 2004). Recent work has discovered that dying neutrophils release long
filament of genomic DNA, termed Neutrophil Extracellular Traps (NETs), in
response to stress and bacterial infection (Brinkmann V et al, 2004; Fuchs T et
al, 2007). This interesting type of cell death induced in neutrophils has been
given the name NETosis. Interestingly these NETs contain the granule-derived
antimicrobial peptides LL37 and HNP and they are believed to play a role in
killing bacteria trapped on these NET (Brinkmann V et al, 2007). Thus presence
of both the antimicrobial peptides and genomic DNA in the NETs and circulating
apoptotic neutrophils in Lupus, together point to strong possibility of these NETs
to be the source of the DNA-LL37 particulate complexes contained in the Lupus
immune complexes. We investigated the possibility of finding nucleaseinsensitive domains in the NETs produced by neutrophils in response to
nonspecific activation with phorbol myristate acetate. We found the long
filaments of DNA on the NET structures disappeared on DNase treatment leaving
behind protected DNA particles quite similar in morphology to the small micronrange particulate complexes found in the immune complexes and with in vitro
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Figure 2.28

Figure 2.28. Nuclease-resistant domains in neutrophil-derived NET-DNA. Neutrophils
were stimulated with PMA to induce NETosis on coverslips. NET-DNA was stained with
DAPI and imaged under a confocal microscope with (right panel) or without (left panel) a 30min pretreatment with DNase I. Bar = 10 µm.
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formed complexes (Figure 2.28). The size and the characteristic morphology of
NET-derived DNA particles and their resistance to DNase degradation and
presence of antimicrobial peptide LL37 on the NETs as shown earlier, suggests
that NETs can be the potential source of self-DNA in immune complexes in SLE
patients.

Autoantibodies to the antimicrobial peptides can drive neutrophil NETosis
Although our experiments gave suggestive evidence for the NETs being potential
source of the nucleic acid-AMP particles in the Lupus immune complexes,
question remained about the cause of the NETosis process in SLE. Neutrophil
cell death associated with the original description of NETosis was triggered by
microbial infections (Brinkmann V et al, 2007). However, a very recent study
reported that auto-antibodies against the enzymes myeloperoxidase and
elastase, which are also present in the secretory granules in neutrophils, are able
to trigger the release of NETs and inducing cell death (Kessenbrock K et al,
2009). Interestingly, studies done by others in our lab (Lande R et al, 2010) had
revealed presence of auto-antibodies to the endogenous antimicrobial peptides
LL37 and HNP in SLE sera. This led us to investigate whether auto-antibodies
against these neutrophil-derived antimicrobial peptides can also trigger the
process of NETosis. We found that antibodies against LL37 and HNP can induce
NETosis in neutrophils (Figure 2.29.A&B), while anti-DNA antibodies and
relevant isotype antibodies were not able to do the same. To exclude the role of
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Figure 2.29
A

B

Figure 2.29. The release of NETs by neutrophils is triggered by autoantibodies to
antimicrobial peptides. Purified neutrophils from healthy donors were incubated for 3 h
with anti-LL37 (8A8), anti-LL37 (8A8) Fab, anti-HNP, anti-DNA (H241), control IgG
antibodies, or phorbol myristate acetate (PMA) and analyzed for NET formation by confocal
microscopy. (A) Representative confocal images of NET induction in stimulated neutrophils.
(B) NET density values, scored from 1 to 10 in multiple independent experiments, are given;
horizontal line represents the mean. *, p = 0.024; **, p < 0.001; ***, p = 0.006; ANOVA
(adjusted for Dunnett’s test).
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cell surface Fc receptor in this antibody-induced cell death we also used F(ab)2
fragment of the anti-LL37 antibody and found that it was also able to induce
similar NETosis (Figure 2.29.A&B).
Taken together we found that auto-antibodies against neutrophil derived
antimicrobial peptides produced in SLE lead to neutrophil cell death and release
of extracellular NETs. These NETs are known to contain the same antimicrobial
peptides on them and they are potentially digested by extracellular nucleases
leaving behind smaller nucleic acid-AMP particulate domains that are relatively
resistant to nuclease degradation. These particulate complexes along with the
anti-DNA antibodies constitute the Lupus immune complexes.
These data brings further support in favor of our general hypothesis that the
electrostatic interaction between endogenous antimicrobial peptides with self
nucleic acid molecules occur in physiological conditions and leads to the
formation of nucleic acid-peptide complexes in vivo. These complexes can then
access the endosomal compartments in the dendritic cell subsets and trigger tolllike receptor activation, and thus incite activation of innate immune response to
self nucleic acids initiating an autoimmune inflammatory cascade.
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3. General Discussion
and
Future Directions
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Host cell death is associated with release of the nucleic acid content of these
cells into the extracellular space. While innate immune system is able to
recognize the nucleic acid molecules and initiate inflammation, more often this
results from recognition of nucleic acid molecules of foreign origin derived from
microbial invaders. The reasons for this fact of extracellularly released nucleic
acid molecules of self-origin usually failing to initiate similar inflammatory
cascade, are thought to be structural differences between the nucleic acid
molecules from higher organisms compared to those from microbial pathogens
and very efficient degradation of the extracellularly released self-nucleic acids by
the extracellular nucleases (discussed in Section 1.4). Moreover the toll-like
receptors that are able to recognize different species of nucleic acids are located
inside the endosomal compartments of the innate immune cells. Nucleic acid
molecules of self-origin cannot normally access these endosomal compartments
and thus fail to trigger TLR activation.

In our studies we found that an endogenous peptide can circumvent these
barriers and bring about innate immune recognition of self-nucleic acids by
binding to and transporting the nucleic acid molecules into the endosomal
compartments of dendritic cells. First a study by Lande R et al in our lab
identified this endogenous peptide LL37, an antimicrobial peptide of Cathelicidin
family, in the context of self-DNA recognition in plasmacytoid dendritic cells
(Lande R et al, 2007). Then we found in our studies with nucleic acids released
by dying human cells, that this pathway is operative in the recognition of these
host cell-derived nucleic acids and both DNA and RNA molecules released in this
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situation can activate pDCs. As expected we found that the LL37 peptide is also
able to interact with and transport RNA molecules into the endosomal
compartments of dendritic cells (Ganguly D et al, 2009). Extracellular self-RNA
usually cannot lead to innate immune activation because of its exquisite
susceptibility to extracellular RNases and as it cannot to enter the endosomal
compartments of the dendritic cells to access the RNA-recognizing TLRs. But in
our studies we found that the cationic antimicrobial peptide LL37 can also go into
a charge-based interaction with self-RNA, like it had been shown with DNA
molecules previously (Lande R et al, 2007).

More importantly we found that this interaction between the cationic peptide and
anionic nucleic acid molecules form microscopically visible aggregates of
particulate complexes by condensing the nucleic acid molecules and these
complexes are protected from enzymatic degradation (described in Section 2.1;
Ganguly D et al, 2009). Thus inherent susceptibility of RNA molecules to
nucleases is circumvented, thus enabling the self-RNA molecules in these
complexes to be available for transport into the endosomal compartments of
dendritic cells and access the TLRs. Ability of LL37 to transport self-RNA
molecules into the innate immune cells broadens the implications of this
pathway, as in addition to pDCs, mDCs can also recognize RNA molecules in
their endosomal compartments due to expression of multiple RNA-responsive
TLRs. We found that the self-RNA-LL37 complexes trigger TLR7 activation in
pDCs to induce production of type I IFNs, on the other hand these complexes
induce mDC activation through TLR8 leading to maturation of those mDCs and
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production of the proinflammatory cytokines TNF-α and IL-6 (depicted in Section
2.2; Ganguly D et al, 2009). Possibility of mDC activation, in addition to activation
of the pDCs, implies a wider propagation of the inflammatory cascade.

The formation of the nucleic acid-AMP complexes is mediated by electrostatic
interaction between the cationic residues on the peptide and the anionic
phosphate backbone of the nucleic acid (Lande R et al, 2007; Ganguly D etal,
2009). It has been proposed that the alpha-helical domains of LL37 stabilize the
interactions with the double-stranded DNA molecules (Sandgren S et al, 2004).
Human RNA is single-stranded but LL37 may preferentially bind the regions
where the RNA molecule folds into complex structures like double helical regions
with hairpin or internal loops. The conversion of the non-stimulatory self-RNA
molecules into a trigger of TLR7 and TLR8 in the dendritic cells seem to result
from two distinct events — the electrostatic interaction with LL37 condenses the
RNA molecules into compacted and aggregated structures that are relatively
resistant to enzymatic degradation, which in turn is critical for its availability for
the next event of internalization of the nucleic acid molecules into endosomal
compartments. A recent paper shows that pDCs are particularly efficient in
phagocytosing a particulate antigen load or TLR ligands, although their
macropinocytosis efficiency in case of soluble antigens is not significant (Tel J et
al, 2010). Thus the particulate complex formation from the interaction of self
nucleic acid molecules with the cationic peptides lead to efficient internalization
of these self-ligands for triggering endosomal TLRs. Moreover, the nano-scale
size distribution of the unit constituent particles in the particulate micro-
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aggregates formed by self-RNA and LL37, as resolved by the electron
microscopic studies and particle sizing experiments (discussed in Section 2.1;
Ganguly D et al, 2009), also may play an important role in their immunogenicity
and dendritic cell activation due to higher efficiency in the internalization of the
constituent TLR ligands. A recent study revealed that RNA molecules presented
in nano-scale particles are selectively phagocytosed by pDCs, triggering TLR7
and inducing IFN-α production in them (Rettig L et al, 2010). These studies
reaffirmed the physio-pathological significance of the nano-scale particle
formation in the interaction between self nucleic acids and the cationic peptide.

Inside the endosomes self-RNA binds and activates TLR7 and TLR8 that
recognize uridine residues present in both viral RNA and RNA of self-origin
(Diebold SS et al, 2006). Conventional views about distinction of nucleic acid
molecules of self and non-self origin is that self-RNA is highly enriched with
several nucleoside modifications like methylation or presence of pseudouridines
that make it unable to activate TLR7 and TLR8 (Kariko KM et al, 2005; Robbins
MA et al, 2007). The same is proposed to explain the distinction of DNA
molecules of self-origin, which have methylated CpG motifs. But our findings, that
total cellular RNA isolated from human cells or released during host cell death is
able to trigger TLR activation, indicates that even in the presence of these
nucleoside modifications, non-modified sequences that are retained in
mammalian RNA can induce innate immune activation. But the protection of
these RNA sequences from extracellular degradation and their transport into the
endosomal compartments, so that they can access the TLRs, are important

123
prerequisites. This view is supported by previous studies, which showed the
ability of self-RNA to trigger TLR7 activation when they were transfected into
DCs through lipofection (Kariko KM et al, 2005).

As an indication in support of our hypothesis, that this immune recognition of
self-nucleic acids driven by this endogenous antimicrobial peptide can be pathophysiologically relevant and may drive the autoimmune inflammation in human
clinical conditions, we could find nucleic acid-LL37 complexes as small
extracellular particles in cryosections of the lesional skin from psoriatic patients.
We could find both DNA and RNA particles and on a lot of these particles we
could detect the presence of LL37 (depicted in Section 2.3.A; Ganguly D et al,
2009). This demonstrated that this interaction between the cationic peptide and
the anionic nucleic acid molecules can occur and the particulate complexes can
form in vivo in the context of an autoimmune inflammation. Moreover, we found a
lot of these particulate complexes to be around clusters of mature dendritic cells
in the lesions. Occasionally we could even find some activated mDCs with
multiple RNA particles within their endolysosomal vesicular network. The relative
abundance of the RNA particles also correlated with the number of activated
mDCs in the lesional cellular infiltration. These findings provided strong evidence
that self-RNA-LL37 particles can form in vivo and can activate mDCs in psoriatic
lesions.

Psoriatic lesions are characterized by infiltration of pDCs early during the course
of disease progression and type I IFNs produced by these pDCs have been
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shown to be instrumental for the initiation of the disease process (Nestle FO et
al, 2005). However, at later stages of pathogenesis the cellular infiltrate in the
psoriatic lesions is characterized by relative absence of pDCs and presence of
large numbers of activated and mature myeloid DCs, which are able to stimulate
pathogenic T cells thus driving the inflammation (Nestle FO et al, 2005; Albanesi
C et al, 2009). PDC infiltration early in the disease process has been attributed to
the expression of the chemokine Chemerin by dermal fibroblasts and presence of
the ChemR23 receptor on the infiltrating pDCs early in pathogenesis, which is
absent in the chronic plaque form of the disease (Albanesi C et al, 2009). Based
on these reports and the findings from our studies, we propose that RNA-AMP
and DNA-AMP complexes may drive a concerted activation of pDC and mDC
initiating the early inflammatory process in psoriasis. While at the later stages of
the more chronic form of the disease, inflammation may be exclusively driven by
the mature mDCs activated by RNA-AMP complexes.

Finding similar electrostatic interaction between the cationic AMPs and self
nucleic acids in our studies with immune complexes isolated from sera of SLE
patients brought further support to our notion, that this phenomenon of nucleic
acid complexes being formed and driving autoimmune inflammation operates in
vivo (discussed in Section 2.3.B; Lande R et al, 2010). We found that Lupus
immune complexes form particulate complexes, similar to what we found in vitro
or in situ Psoriatic lesions, and the nucleic acid molecules contained in these
complexes are protected from enzymatic degradation due to the presence of the
cationic AMPs (Lande R et al, 2010). When this electrostatic interaction is
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inhibited, by using an anionic polypeptide, the visible particulate complexes
disappear, thus demonstrating that the structural integrity of the immune
complexes is due to this interaction with cationic AMPs and resulting
condensation of the nucleic acid molecules. Also the susceptibility from
enzymatic degradation, which is a very important issue for extracellular existence
of the immune complexes, were found to reduce in presence of the cationic
peptides, while the anti-nucleic acid antibodies contained in the complexes seem
unable to revert this susceptibility (described in Section 2.3.B).

Activation-induced neutrophil death and associated release of genomic DNA in a
filamentous network structure called NETs is a recently described antimicrobial
effector mechanism (Brinkmann V et al, 2004; Brinkmann V et al, 2007). Original
description depicted that on bacterial infection the NETs are generated from the
apoptosing neutrophils (by a process termed NETosis). The released NETs are
studded with antimicrobial peptide stored in neutrophil granules and the bacteria,
after getting trapped on the sticky DNA filaments, get killed by those antimicrobial
peptides (Brinkmann V et al, 2004). This report of extracellular release of DNA
filaments studded with antimicrobial peptides, along with the reports showing
high numbers of apoptotic neutrophils in SLE patients, that correlated with
disease progression, led us to hypothesize that NETosis process of the apoptotic
neutrophils in SLE may be a potential source of the nucleic acid-AMP complexes
found in lupus immune complexes. Particulate domains of NET DNA remaining
after DNase treatment, while longer stretches of DNA filaments disappear,
provided suggestive evidence in support of this hypothesis (discussed in Section
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2.3.B; Lande R et al, 2010), but the question remained about the trigger of this
process in NETosis. While hyper-activation of neutrophils in response to
nonspecific stimuli like phorbol esters or microbial infection have been shown to
induce the NETosis process in the original studies, a very recent study showed
autoantibodies to neutrophil granule-derived enzymes like myeloperoxidase and
elastase can also induce neutrophil death associated with release of NETs
(Kessenbrock K et al, 2009). Interestingly other studies done in our lab revealed
the presence of autoantibodies to the neutrophil-derived AMPs in the sera from
SLE patients (Lande R et al, 2010). So we investigated whether these
autoantibodies can also induce NETosis in neutrophils and found that the
autoantibodies to the neutrophil-derived AMPs could indeed induce apoptosis in
neutrophils and subsequent release of NETs (described in Section 2.3.B; Lande
R et al, 2010). Thus taking all these findings together we could gather strong
support in favor of our hypothesis that the neutrophil-NET-derived nucleic acidAMP complexes are present in the lupus immune complexes and the presence of
AMPs in these complexes determines the structural integrity and immunogenicity
of these complexes.

The antimicrobial peptide LL37 is typically expressed in the epithelial cells in
different parts of the body or released by neutrophils and the expression occurs
in the context of infection or other types of tissue injury. Although the exact
mechanisms of LL37 expression are not yet fully understood, recent studies
report the involvement of the vitamin D3 metabolic pathway and the hypoxia
response pathways, in addition to role of microbial infection (Liu PT et al, 2006;
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Schauber J et al, 2007; Peyssonnaux C et al, 2008). In the psoriatic lesions LL37
shows a sustained overexpression by the keratinocytes, which then can lead to
continuous formation of the nucleic acid complexes that we described in our
studies leading to innate immune activation through the toll-like receptors. The
resulting uncontrolled and continuous activation of both pDCs and mDCs then
may lead to the induction of high-levels of autoreactive T cells and development
of the inflammatory process toward an overt autoimmune clinical condition. On
the contrary, induction of LL37 expression in skin injuries is transient and may
drive low levels of innate immune activation and inflammatory response helping
in wound healing. However it is also possible that this transient LL37 expression
and innate immune activation in skin injuries may induce low levels of
autoreactive T cells, although the extent is insufficient to drive an overt
autoimmune process. Recent studies report activation of T cells on injury, which
then participate in wound healing (Toulon A et al, 2009). It may also be that the
transient innate immune activation in tissue injury can only allow activation of T
cells specific for high-avidity antigens derived from invading pathogens thus
precluding the activation of autoreactive T cells.

The notion derived from the studies we did is that any clinical condition, with
availability of high levels of the antimicrobial peptide LL37 along with extracellular
release of self nucleic acid, should be susceptible to this innate immune
activation resulting from immune recognition of the self nucleic acid molecules.
We found evidences that support this notion in the cutaneous inflammatory
disease Psoriasis and in the systemic autoimmune disease SLE. Keratinocyte-
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Figure 3.1

Figure 3.1. Self nucleic acid sensing leading to pDC activation in tissue injury and
autoimmunity. The antimicrobial peptide LL37, secreted by epithelial cells in response to
injury or tissue-infiltrating activated neutrophils, binds self-nucleic acid molecules released
by dying cells, forming condensed complexes that are protected from extracellular nuclease
degradation and delivered endosomal compartments of plasmacytoid dendritic cells (pDCs).
A similar event is proposed to occur in the cutaneous autoimmune disease psoriasis,
leading to the pathogenetic inflammatory process. In the systemic autoimmune disease
SLE, anti-DNA autoantibodies produced by autoreactive B cells can bind to these self-DNA–
LL37 complexes, thereby potently enhancing their translocation into the pDC endosomes
through Fc receptors. (Modified from Gilliet M et al, 2008, with permission from Nature
Reviews Immunology)
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derived LL37 in Psoriasis and the neutrophil-derived nucleic acid-peptide
complexes in SLE seem to play a major role in the innate immune activation in
these clinical conditions. Other chronic inflammatory diseases like rosacea
(Yamasaki K et al, 2007), rheumatoid arthritis (Paulsen F et al, 2002), colitis
ulcerosa (Schauber J et al, 2003), chronic nasal inflammatory disease (Kim ST et
al, 2003), sarcoidosis (Agerberth B et al, 1999) and cystic fibrosis (Bucki R et al,
2007) have also been reported to be associated with persistent high levels of
LL37. Thus one may speculate that in these clinical conditions also the self
nucleic acid-LL37 complexes may form and play a role to sustain the
inflammatory responses through TLR-mediated activation of dendritic cells
(Figure 3.1).

Thus one may envisage therapeutic strategies to inhibit the

expression of LL37 or the formation of LL37-nucleic acids complexes that can be
explored in a lot of these clinical conditions.

Other questions that remain to be addressed are involvement of other
endogenous cationic peptides in the body in similar pathway of innate immune
activation. Some of the other antimicrobial peptides like beta defensins also have
cationic amphipathic properties, thus making them strong candidates for this
pathway of self nucleic acid recognition. Defensins also have been found to be
overexpressed in Psoriatic epidermis both in studies done by us (data not shown
in this dissertation) and by others (Peric M et al, 2009). So it is important to look
for similar interaction with nucleic acids using these peptides and to investigate
whether they also participate in this break of innate tolerance to self nucleic acids
thus contributing in autoimmune clinical contexts. Ongoing studies in our lab are
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exploring these possibilities. Some of the RNA-complexes that we found in situ in
Psoriatic lesional skin were found to be negative for LL37, creating the possibility
of other peptides taking part in this complex formation.

Clinical trials of therapeutic agents that target the inflammatory molecules in the
body have confirmed major involvement of TNF-α in the pathogenetic process in
Psoriasis, as inhibition of this cytokine action showed clinical improvements in
patients (Mease PJ et al, 2000; Chaudhari U et al, 2001). But this sort of
interventions target downstream genes in the pathway. A proximal target like the
cationic peptide itself or measures that may affect clearance of extracellular
nucleic acids should also be explored in psoriasis and other related clinical
conditions. Although type I IFNs have been shown to be instrumental for the
initiation of the disease process in Psoriasis (Nestle FO et al, 2005), a recent
study found no clinical effect of an anti-IFN-α antibody (Bissonnette R et al,
2010). But this trial was conducted with patients with Chronic Plaque Psoriasis
and the antibody used failed to show any inhibition of type I IFN gene signature.
Although pDC-derived type I IFNs have been shown to play a defining role in the
initiation of the disease process, at chronic phase of the disease recruitment and
activation of the myeloid DCs seem to be the predominant feature. Thus one may
speculate that self-RNA-LL37 induced induction of proinflammatory cytokines
seem to gain more importance in the chronic phase of the disease and type I
IFNs at this phase work mainly toward enhancement of the mDC maturation and
the general inflammatory process for which we have support from our in vitro
experiments.
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Tumor microenvironment is predominated by immunosuppressive cytokines and
cellular effectors that prevent any efficient anti-tumor immunity to be operative.
Activated effector cells like tumor antigen-primed dendritic cells or antigenspecific T cells have been in use for cancer immunotherapy trials (Finn OJ,
2008). But an intratumoral immunosuppressive milieu driven by the tumor cells
and also by the immune cells that infiltrate the tumor comes in the way. Immunoadjuvant therapies to potentiate directed immunotherapy have also been
explored in association with specific immuno-therapies (Finn OJ, 2008). One of
the strategies for such adjuvant therapies is using the TLR9 agonist CpG
oligonucleotides to induce dendritic cell activation. In mouse models of tumors
these TLR9 agonists have been shown to be active alone or in combination with
cancer vaccines, tumor antigen specific antibodies, adoptive cellular therapies,
radiotherapy and chemotherapies. Phase I and II clinical trials done with these
molecules showed promise as single agents or as therapeutic vaccine adjuvants
(Vollmer J et al, 2009). Keeping these studies in mind one might speculate about
the potentials of an antitumor therapeutic strategy mediated through the pathway
described here for immune recognition of self nucleic acids. Tumor cores are
seat of continual cell death due to hypoxia and high cell turn over and thus rich in
nucleic acids that are released extracellularly. Delivery of the cationic peptide
molecules inside the tumor core, with the intention of triggering immunogenic
complex formation with self nucleic acids released in the tumor stroma, and thus
driving innate immune activation through toll-like receptors in the tumor infiltrating
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Figure 3.2

Figure 3.2. Endogenous cathelicidin mediated innate recognition of nucleic acids can
play roles in both sterile and non-sterile inflammation. The endogenous cathelicidin
antimicrobial peptide LL37 can bind self nucleic acid molecules extracellularly released by
dying host cells in case of sterile or non-sterile injury, leading to TLR-mediated activation of
dendritic cells and immune response propagation. In case of infection the microbial nucleic
acids can also potentially be bound by LL37leading to efficient intra=endosomal transport
and dendritic cell activation. The tissue injury processes themselves lead to over-expression
of the cathelicidin peptide in the vicinity thus driving the inflammatory process. (Modified
from Lee DJ et al, 2008, with permission from Nature Medicine)
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antigen presenting cells, may be envisaged as a viable therapeutic strategy
which remains to be explored.

On a broader perspective our studies describe a novel cell death sensing
mechanism that can lead to a potent innate immune response by activating
different subsets of dendritic cells through immune recognition of self nucleic acid
molecules by toll-like receptors. Involvement of both DNA (Lande R et al, 2007;
Ganguly D et al, 2009; Lande R et al, 2010) and RNA (Ganguly D et al, 2009)
molecules in this pathway widens the downstream cascade. Protection of
extracellular nucleic acids in presence of the cationic peptide leads to particulate
complexes to form in the body thus constituting a potent danger signal for tissue
injury and host cell death (Figure 3.2). In addition to innate immune activation in
response to nucleic acid molecules of self-origin, whether this pathway may also
operate in other clinical settings associated with microbial infection, taking part in
the sensing of nucleic acids of microbial origin and resulting inflammatory
processes, remains to be seen.
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